busulfan and Acute Myelogenous Leukemia studies

Research Excerpts

Excerpt	Relevance	Reference
"Therapeutic options for patients with polycythemia vera (PV) and essential thrombocythemia (ET) resistant or intolerant to hydroxyurea are limited."	9.19	Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. ( Alvarez-Larrán, A; Ancochea, A; Angona, A; Antelo, ML; Bellosillo, B; Besses, C; Burgaleta, C; Cervantes, F; Durán, MA; Ferrer-Marín, F; Gómez, M; Gómez-Casares, MT; Hernández-Boluda, JC; Marcote, B; Martínez-Avilés, L; Martínez-Trillos, A; Mata, MI; Senín, A; Vicente, V; Xicoy, B, 2014)
"In this prospective study 60 patients of median age 46 (range: 5-60 years), with acute myelogenous leukemia (AML; n = 44), acute lymphoblastic leukemia (ALL; n = 3), or myelodysplastic syndrome (MDS; n = 13) were conditioned for allogeneic hematopoietic cell transplantation with a treosulfan/fludarabine (Flu) combination."	9.15	Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. ( Appelbaum, FR; Bedalov, A; Deeg, HJ; Doney, KC; Flowers, ME; Guthrie, KA; Hilger, RA; Kovacsovics, TJ; Maziarz, RT; Nemecek, ER; Pagel, JM; Sanders, JE; Scott, BL; Sickle, EJ; Sorror, ML; Witherspoon, R; Wood, BL; Woolfrey, AE, 2011)
"Sixty-two adults underwent marrow or blood stem cell transplantation from an HLA-matched related donor using high-dose thiotepa, busulfan, and cyclophosphamide (TBC) as the preparative regimen for treatment of advanced myelodysplastic syndrome (MDS) (refractory anemia with excess blasts with or without transformation) or acute myelogenous leukemia (AML) past first remission."	9.09	Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. ( Abi-Said, D; Anderlini, P; Andersson, BS; Andreeff, M; Bibawi, S; Braunschweig, I; Champlin, R; Claxton, D; Donato, M; Estey, EH; Fayad, L; Gajewski, J; Giralt, S; Khouri, I; Mehra, R; Przepiorka, D; Ueno, NT; van Besien, K, 2001)
"The use of cyclosporine-A/methotrexate (CyA/MTX) for graft-versus-host disease (GVHD) prophylaxis is safe and effective for patients undergoing allogeneic bone marrow transplantation after preparation with cyclophosphamide and total body irradiation."	9.07	Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide. ( Essell, JH; Halvorson, RD; Harman, GS; Johnson, RA; Rubinsak, JR; Snyder, MJ; Thompson, JM, 1992)
" busulfan (Bu) has been the main conditioning regimens for allogeneic hematopoietic cell transplantation (alloHCT) for young patients with acute myelogenous leukemia (AML) eligible for a myeloablative conditioning (MAC) regimen."	7.96	Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Up fro ( Al Malki, MM; Aldoss, I; Ali, H; Aribi, A; Armenian, S; Budde, E; Dadwal, S; Dandapani, S; Forman, SJ; Hui, S; Khaled, S; Marcucci, G; Mei, M; Mokhtari, S; Murata-Collins, J; Nakamura, R; Peng, K; Pullarkat, V; Salhotra, A; Sandhu, KS; Snyder, D; Spielberger, R; Stein, A; Teh, JB; Wong, J; Yang, D, 2020)
"Fludarabine and melphalan (Flu/Mel) has emerged as a more tolerable chemotherapy-based conditioning regimen compared with busulfan and cyclophosphamide (Bu/Cy) for allogeneic stem cell transplant (allo-hematopoietic stem cell transplantation (HSCT)) patients with acute myelogenous leukemia (AML)."	7.88	Myeloablative busulfan/cytoxan conditioning versus reduced-intensity fludarabine/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemia. ( Connolly, EC; Dhere, V; Edelman, S; Esiashvili, N; Graiser, M; Khan, MK; Langston, A; Switchenko, JM; Waller, EK, 2018)
"In patients with acute myelogenous leukemia, the leukemia-free survival and regimen-related toxicity rates obtained in our study appear similar to those achieved with other preparative regimens, including those containing Cy and total body irradiation (TBI)."	7.77	Allogeneic bone marrow transplantation for acute myelogenous leukemia, acute lymphocytic leukemia, and multiple myeloma following preparation with busulfan and cyclophosphamide (BuCy2). ( Avalos, BR; Biggs, JC; Brodsky, I; Copelan, EA; Crilley, P; Harman, GS; Kapoor, N; Klein, JL; Szer, J; Thompson, JM, 1993)
" busulfan (Bu) is well tolerated and effective in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) for acute myelogenous leukemia (AML)."	7.76	The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia. ( Bahlis, NJ; Balogh, A; Brown, CB; Chaudhry, MA; Daly, A; Duggan, P; Geddes, M; Irish, W; Larratt, L; Quinlan, D; Russell, JA; Savoie, ML; Stewart, DA; Storek, J; Turner, AR; Zacarias, N, 2010)
"To analyze the results of idarubicin (IDA)- versus etoposide (VP16)-intensified myeloablative conditioning regimen in allogeneic hematopoietic stem cell transplantation (allo-SCT) for high-risk acute leukemia."	7.75	A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia. ( Chen, ZC; Li, L; Li, QB; Xia, LH; You, Y; Zou, P, 2009)
" We reviewed our experience using busulfan and cyclophosphamide (CY), instead of TBI, as the preparative regimen for allogeneic BMT to study the incidence and relationship to graft-versus-host disease (GVHD) of post-treatment eosinophilia."	7.69	Eosinophilia after allogeneic bone marrow transplantation using the busulfan and cyclophosphamide preparative regimen. ( Bolwell, BJ; Kalaycioglu, ME, 1994)
"Cutaneous graft-versus-host disease (GVHD) has been reported after administration of cyclosporine (CSP) after autologous bone marrow transplantation (ABMT) with unpurged marrow in patients with lymphoma."	7.68	Induction of cutaneous graft-versus-host disease by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia. ( Altomonte, V; Farmer, ER; Hess, AD; Jones, RJ; Santos, GW; Vogelsang, GB; Yeager, AM, 1992)
"Clofarabine has potent antileukemia activity and its inclusion in reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (HSCT) for acute leukemia could potentially improve outcomes."	6.82	Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Acute Lymphoid Leukemia. ( Alyea, E; Ballen, KK; Chen, YB; Cutler, C; Dey, BR; Driscoll, J; El-Jawahri, A; Ho, VT; Hunnewell, C; Li, S; McAfee, SL; Poliquin, C; Saylor, M; Soiffer, RJ; Spitzer, TR, 2016)
" The aim of this study was to determine the appropriate dosing of etoposide in combination with busulfan and cyclophosphamide in this setting."	6.69	Hematopoietic stem cell transplantation (HSCT) with a conditioning regimen of busulfan, cyclophosphamide, and etoposide for children with acute myelogenous leukemia (AML): a phase I study of the Pediatric Blood and Marrow Transplant Consortium. ( Coppes, MJ; Gamis, A; Hagg, R; Kamani, N; Mustafa, MM; Sandler, ES; Wall, D, 2000)
"Busulfan is a commonly used chemotherapeutic agent in myeloablative conditioning regimens for allogeneic hematopoietic cell transplantation (allo-HCT)."	5.42	Subacute hepatic necrosis mimicking veno-occlusive disease in a patient with HFE H63D homozygosity after allogeneic hematopoietic cell transplantation with busulfan conditioning. ( Boyer, MW; Chen, S; Chen, X; Hildebrandt, GC; McDonald, GB; Osborn, JD, 2015)
" We retrospectively compared outcomes of a consecutive series of 51 AML patients treated with oral busulfan (1 mg/kg every 6 hours for 4 days) and cyclophosphamide (60 mg/kg IV × 2 days) - (Bu/Cy) with 100 consecutive AML patients treated with pharmacokinetic targeted IV busulfan (AUC < 6000 μM/L*min per day × 4 days) and fludarabine (40 mg/m2 × 4 days) - (t-IV Bu/Flu)."	5.36	Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia. ( Anasetti, C; Fernandez, HF; Field, T; Kharfan-Dabaja, MA; Kim, J; Nishihori, T; Perez, L; Perkins, J; Pidala, J, 2010)
"Busulfan is a carcinostatic which is used for myelocytic leukemia."	5.30	Cataract induced by short-term administration of large doses of busulfan: a case report. ( Amemiya, T; Kaida, T; Ogawa, T, 1999)
"Twenty-five consecutive patients with acute myelogenous leukemia (AML) underwent 26 allogeneic bone marrow transplants at Hahnemann University Hospital."	5.28	Bone marrow transplantation following busulfan and cyclophosphamide for acute myelogenous leukemia. ( Bigler, R; Brodsky, I; Bulova, S; Crilley, P; Topolsky, D, 1990)
" busulfan as myeloablative therapy for autologous HSCT in AML is safe, with mucositis being the most significant toxicity."	5.20	A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia. ( Ai, WZ; Andreadis, C; Benet, LZ; Damon, LE; Gaensler, KM; Kaplan, LD; Koplowicz, YB; Linker, CA; Logan, AC; Mannis, GN; Martin, TG; Olin, RL; Sayre, PH; Smith, CC; Sudhindra, A; Venstrom, JM; Wolf, JL, 2015)
"Therapeutic options for patients with polycythemia vera (PV) and essential thrombocythemia (ET) resistant or intolerant to hydroxyurea are limited."	5.19	Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. ( Alvarez-Larrán, A; Ancochea, A; Angona, A; Antelo, ML; Bellosillo, B; Besses, C; Burgaleta, C; Cervantes, F; Durán, MA; Ferrer-Marín, F; Gómez, M; Gómez-Casares, MT; Hernández-Boluda, JC; Marcote, B; Martínez-Avilés, L; Martínez-Trillos, A; Mata, MI; Senín, A; Vicente, V; Xicoy, B, 2014)
"In this prospective study 60 patients of median age 46 (range: 5-60 years), with acute myelogenous leukemia (AML; n = 44), acute lymphoblastic leukemia (ALL; n = 3), or myelodysplastic syndrome (MDS; n = 13) were conditioned for allogeneic hematopoietic cell transplantation with a treosulfan/fludarabine (Flu) combination."	5.15	Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. ( Appelbaum, FR; Bedalov, A; Deeg, HJ; Doney, KC; Flowers, ME; Guthrie, KA; Hilger, RA; Kovacsovics, TJ; Maziarz, RT; Nemecek, ER; Pagel, JM; Sanders, JE; Scott, BL; Sickle, EJ; Sorror, ML; Witherspoon, R; Wood, BL; Woolfrey, AE, 2011)
" busulfan (Bu) and fludarabine (Flu) is a safe, reduced-toxicity conditioning program for acute myelogenous leukemia/myelodysplastic syndromes (AML/MDS), recurrent leukemia posttransplantation remains a problem."	5.15	Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. ( Alousi, A; Andersson, BS; Champlin, RE; de Lima, M; Hosing, C; Jones, RB; Kebriaei, P; Madden, T; Popat, U; Rondon, G; Shpall, EJ; Thall, PF; Valdez, BC; Wang, X; Worth, LL, 2011)
" To account for improved supportive care and other unidentified factors that may affect outcome ("period" effects), 78 acute myelogenous leukemia (AML) patients receiving Melphalan-Flu (MF), treated in parallel during this time (1997-2004) were used to estimate the period effect."	5.13	Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. ( Andersson, BS; Champlin, RE; Couriel, D; de Lima, M; Giralt, S; Jones, RB; Korbling, M; Pierre, B; Roberson, S; Russell, JA; Shpall, EJ; Thall, PF; Wang, X, 2008)
" Methotrexate only was given for graft-versus-host disease (GVHD) prophylaxis."	5.11	Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survival. ( Alonzo, TA; Barnard, DR; Buxton, AB; Gold, S; Kalousek, D; Kobrinsky, N; Lange, BJ; Neudorf, S; Sanders, J; Wallace, JD; Woods, WG, 2004)
" We report the results of allografting following conditioning with fludarabine, busulphan, and alemtuzumab in 62 patients with myelodysplastic syndromes (MDSs) (matched sibling donors [24] or volunteer unrelated donors [VUDs, 38])."	5.11	Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. ( Devereux, S; Ho, AY; Kenyon, M; Mijovic, A; Mufti, GJ; Pagliuca, A; Parker, JE, 2004)
" Between March 1993 and June 2002, we treated 33 relapsed acute myelogenous leukemia (AML) patients with busulfan-based preparative regimens and selective TCD."	5.11	CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens. ( Andresen, S; Ball, E; Bolwell, B; Cook, D; Kalaycio, M; Kuczkowski, E; Pohlman, B; Rybicki, L; Sobecks, R, 2005)
"Sixty-two adults underwent marrow or blood stem cell transplantation from an HLA-matched related donor using high-dose thiotepa, busulfan, and cyclophosphamide (TBC) as the preparative regimen for treatment of advanced myelodysplastic syndrome (MDS) (refractory anemia with excess blasts with or without transformation) or acute myelogenous leukemia (AML) past first remission."	5.09	Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. ( Abi-Said, D; Anderlini, P; Andersson, BS; Andreeff, M; Bibawi, S; Braunschweig, I; Champlin, R; Claxton, D; Donato, M; Estey, EH; Fayad, L; Gajewski, J; Giralt, S; Khouri, I; Mehra, R; Przepiorka, D; Ueno, NT; van Besien, K, 2001)
" Cyclosporin A and short methotrexate were used for graft-versus-host disease (GVHD) prophylaxis."	5.08	Combined transplantation of allogeneic bone marrow and CD34+ blood cells. ( Arseniev, L; Bähre, O; Battmer, K; Berenson, RJ; Casper, J; Diedrich, H; Jacobs, R; Kadar, JG; Kühl, J; Link, H; Poliwoda, H; Schubert, J, 1995)
"The use of cyclosporine-A/methotrexate (CyA/MTX) for graft-versus-host disease (GVHD) prophylaxis is safe and effective for patients undergoing allogeneic bone marrow transplantation after preparation with cyclophosphamide and total body irradiation."	5.07	Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide. ( Essell, JH; Halvorson, RD; Harman, GS; Johnson, RA; Rubinsak, JR; Snyder, MJ; Thompson, JM, 1992)
"Sixteen patients with poor-prognosis acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and non-Hodgkin's lymphoma (NHL) underwent conditioning with busulfan (16 mg/kg) and cyclophosphamide (120 mg/kg) (BUCY-2) plus melphalan (90 or 135 mg/m2) and autologous bone marrow transplantation (AuBMT) in a phase I study."	5.07	Busulfan, cyclophosphamide, and melphalan conditioning for autologous bone marrow transplantation in hematologic malignancy. ( Barnett, MJ; Chan, KW; Klingemann, HG; Lansdorp, PM; Nevill, TJ; Phillips, GL; Reece, DE; Shepherd, JD; Spinelli, JJ, 1991)
" The graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus and short-term methotrexate."	4.12	Donor-derived diffuse large B-cell lymphoma after haploidentical stem cell transplantation for acute myeloid leukemia. ( Ishiguro, C; Kawashiri, A; Kurokawa, T; Maeda, Y; Mochizuki, K; Nakagawa, SI, 2022)
" busulfan (Bu) has been the main conditioning regimens for allogeneic hematopoietic cell transplantation (alloHCT) for young patients with acute myelogenous leukemia (AML) eligible for a myeloablative conditioning (MAC) regimen."	3.96	Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Up fro ( Al Malki, MM; Aldoss, I; Ali, H; Aribi, A; Armenian, S; Budde, E; Dadwal, S; Dandapani, S; Forman, SJ; Hui, S; Khaled, S; Marcucci, G; Mei, M; Mokhtari, S; Murata-Collins, J; Nakamura, R; Peng, K; Pullarkat, V; Salhotra, A; Sandhu, KS; Snyder, D; Spielberger, R; Stein, A; Teh, JB; Wong, J; Yang, D, 2020)
" We describe a protocol that involves pre-conditioning of Casper, a pigmentation mutant of zebrafish with busulfan that led to a higher rate of engraftment of hepatocellular carcinoma and acute myeloid leukemia cells."	3.91	An efficient method to generate xenograft tumor models of acute myeloid leukemia and hepatocellular carcinoma in adult zebrafish. ( Jayandharan, GR; Khan, N; Mahajan, NK; Sinha, P, 2019)
"Fludarabine and melphalan (Flu/Mel) has emerged as a more tolerable chemotherapy-based conditioning regimen compared with busulfan and cyclophosphamide (Bu/Cy) for allogeneic stem cell transplant (allo-hematopoietic stem cell transplantation (HSCT)) patients with acute myelogenous leukemia (AML)."	3.88	Myeloablative busulfan/cytoxan conditioning versus reduced-intensity fludarabine/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemia. ( Connolly, EC; Dhere, V; Edelman, S; Esiashvili, N; Graiser, M; Khan, MK; Langston, A; Switchenko, JM; Waller, EK, 2018)
"25 mg/kg/day on days -4 to -1) and graft-versus-host disease (GVHD) prophylaxis with tacrolimus and methotrexate were used in all patients."	3.81	A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia. ( Cho, BS; Cho, SG; Eom, KS; Jeon, YW; Kim, DW; Kim, HJ; Kim, JH; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, WS; Park, CW; Shin, SH; Yahng, SA; Yoon, JH, 2015)
"To investigate the safety and efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for myelodysplastic syndrome (MDS) and secondary acute myelogenous leukemia (MDS-AML) using conditioning regimen with busulfan (Bu) and increased-dose of fludarabine (ID-Flu)."	3.81	[Combination of busulfan with increased-dose of fludarabine as conditioning regimen for MDS and MDS-AML patients with allo-HSCT]. ( Cen, X; Dong, Y; Li, Y; Liang, Z; Liu, W; Ou, J; Qiu, Z; Ren, H; Sun, Y; Wang, L; Wang, M; Wang, Q; Wang, W; Xu, W; Yin, Y; Yuan, J, 2015)
"Cyclophosphamide (Cy) combined with total-body irradiation (TBI) or with busulfan (Bu) are currently the most common myeloablative regimens used in allogeneic stem-cell transplantation (alloSCT) in adults with acute myelogenous leukemia (AML)."	3.79	Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia worki ( Aljurf, M; Ben Othman, T; Campos, A; Labopin, M; Masszi, T; Michallet, M; Mohty, M; Nagler, A; Passweg, J; Poire, X; Rocha, V; Sengelov, H; Shimoni, A; Socie, G; Unal, A; Veelken, H; Volin, L; Yakoub-Agha, I, 2013)
"In patients with acute myelogenous leukemia, the leukemia-free survival and regimen-related toxicity rates obtained in our study appear similar to those achieved with other preparative regimens, including those containing Cy and total body irradiation (TBI)."	3.77	Allogeneic bone marrow transplantation for acute myelogenous leukemia, acute lymphocytic leukemia, and multiple myeloma following preparation with busulfan and cyclophosphamide (BuCy2). ( Avalos, BR; Biggs, JC; Brodsky, I; Copelan, EA; Crilley, P; Harman, GS; Kapoor, N; Klein, JL; Szer, J; Thompson, JM, 1993)
" busulfan (Bu) is well tolerated and effective in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) for acute myelogenous leukemia (AML)."	3.76	The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia. ( Bahlis, NJ; Balogh, A; Brown, CB; Chaudhry, MA; Daly, A; Duggan, P; Geddes, M; Irish, W; Larratt, L; Quinlan, D; Russell, JA; Savoie, ML; Stewart, DA; Storek, J; Turner, AR; Zacarias, N, 2010)
"To analyze the results of idarubicin (IDA)- versus etoposide (VP16)-intensified myeloablative conditioning regimen in allogeneic hematopoietic stem cell transplantation (allo-SCT) for high-risk acute leukemia."	3.75	A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia. ( Chen, ZC; Li, L; Li, QB; Xia, LH; You, Y; Zou, P, 2009)
" Graft-versus-host disease (GVHD) prophylaxis included methotrexate, cyclosporine A, and rabbit antithymocyte globulin (Thymoglobulin)."	3.74	Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin. ( Bahlis, NJ; Balogh, A; Brown, CB; Chaudhry, MA; Geddes, M; Larratt, L; Quinlan, D; Russell, JA; Savoie, ML; Stewart, DA; Storek, J; Turner, AR, 2007)
"Postulating favorable antileukemic effect with improved safety, we used intravenous busulfan and fludarabine as conditioning therapy for allogeneic hematopoietic stem cell transplantation (HSCT) for acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS)."	3.72	Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. ( Andersson, BS; Champlin, RE; Couriel, D; de Lima, M; Giralt, S; Jones, R; Korbling, M; Madden, T; Pierre, B; Russell, JA; Shahjahan, M; Shpall, EJ; Thall, PF; Wang, X, 2004)
" We evaluated engraftment of all patients with acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML) and myelodysplastic syndrome (MDS) receiving an unmanipulated marrow allogeneic BMT at the Detroit Medical Center from 1987 to 1992 using a busulfan, cyclophosphamide +/- cytarabine preparative regimen."	3.69	Graft failure in children receiving HLA-mismatched marrow transplants with busulfan-containing regimens. ( Abella, E; de Planque, MM; Eisenbrey, AB; Karanes, C; Lum, LG; Ratanatharathorn, V; Ravindranath, Y; Schultz, KR; Sensenbrenner, LL; Uberti, JP, 1994)
" We reviewed our experience using busulfan and cyclophosphamide (CY), instead of TBI, as the preparative regimen for allogeneic BMT to study the incidence and relationship to graft-versus-host disease (GVHD) of post-treatment eosinophilia."	3.69	Eosinophilia after allogeneic bone marrow transplantation using the busulfan and cyclophosphamide preparative regimen. ( Bolwell, BJ; Kalaycioglu, ME, 1994)
"Cutaneous graft-versus-host disease (GVHD) has been reported after administration of cyclosporine (CSP) after autologous bone marrow transplantation (ABMT) with unpurged marrow in patients with lymphoma."	3.68	Induction of cutaneous graft-versus-host disease by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia. ( Altomonte, V; Farmer, ER; Hess, AD; Jones, RJ; Santos, GW; Vogelsang, GB; Yeager, AM, 1992)
" Two patients had been treated with uracil mustard: One developed acute myelogenous leukemia 79 months after institution of therapy, and the other patient developed chronic myelomonocytic leukemia 24 months after the start of therapy."	3.67	Essential thrombocythemia and leukemic transformation. ( Curtis, JL; Levin, J; Sedlacek, SM; Weintraub, J, 1986)
" Grade 3 adverse events included mucositis, diarrhea, and liver transaminitis (n = 3 each)."	3.01	Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active. ( Antin, JH; Brock, J; Cutler, CS; DeAngelo, DJ; Fell, G; Garcia, JS; Gooptu, M; Ho, VT; Karp, HQ; Kim, AS; Kim, HT; Koreth, J; Letai, A; Lindsley, RC; Loschi, F; Lucas, F; Mashaka, T; Murdock, HM; Nikiforow, S; Potter, D; Romee, R; Ryan, J; Shapiro, R; Soiffer, RJ; Stone, RM, 2021)
"Strategies to reduce recurrence are urgently required."	3.01	Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia. ( Andrew, G; Byrne, J; Craddock, C; Crawley, C; Dillon, R; Freeman, SD; Gilleece, M; Hodgkinson, A; Hunter, A; Jackson, A; Khan, N; Loke, J; Malladi, R; Mason, J; McCarthy, N; Nagra, S; Parker, A; Pavlu, J; Peniket, A; Potter, V; Protheroe, R; Salim, R; Siddique, S; Tholouli, E; Vyas, P; Wheatley, K; Wilson, K, 2021)
"Clofarabine has potent antileukemia activity and its inclusion in reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (HSCT) for acute leukemia could potentially improve outcomes."	2.82	Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Acute Lymphoid Leukemia. ( Alyea, E; Ballen, KK; Chen, YB; Cutler, C; Dey, BR; Driscoll, J; El-Jawahri, A; Ho, VT; Hunnewell, C; Li, S; McAfee, SL; Poliquin, C; Saylor, M; Soiffer, RJ; Spitzer, TR, 2016)
" Fifty-eight patients (median age, 67 years; range, 54 to 76) received radioimmunotherapy followed by fludarabine 150 mg/m(2) and busulfan 8 mg/kg combined with either 75 mg (n = 26) or 50 mg (n = 32) alemtuzumab."	2.80	Reduced-Intensity Conditioning Combined with (188)Rhenium Radioimmunotherapy before Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: The Role of In Vivo T Cell Depletion. ( Bornhäuser, M; Ehninger, G; Kotzerke, J; Schetelig, J; Schneider, S; Strumpf, A; Wunderlich, G, 2015)
"Secondary myelodysplastic syndrome and acute myelogenous leukemia (sMDS/sAML) are the most serious secondary events occurring after immunosuppressive therapy in patients with aplastic anemia."	2.79	Hematopoietic stem cell transplantation in children and young adults with secondary myelodysplastic syndrome and acute myelogenous leukemia after aplastic anemia. ( Baumann, I; Führer, M; Furlan, I; Göhring, G; Niemeyer, CM; Nöllke, P; Schlegelberger, B; Schwarz, S; Strahm, B; Teigler-Schlegel, A; Walther, JU; Yoshimi, A, 2014)
"In AML patients, minimal residual disease (MRD; n = 10) at the time of HCT predicted higher relapse incidence (70% versus 18%) and lower OS (41% versus 79%) at 2 years, when compared with patients without MRD."	2.79	Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia. ( Appelbaum, FR; Bar, M; Baumgart, J; Deeg, HJ; Delaney, C; Estey, EH; Fang, M; Gutman, J; Gyurkocza, B; Maziarz, RT; Milano, F; Nemecek, ER; Pagel, JM; Ramakrishnan, A; Sandmaier, BM; Scott, B; Storer, BE; Wood, B, 2014)
"Comparing patients with acute myeloid leukemia/myelodysplastic syndrome versus those with acute lymphoblastic leukemia/bi-phenotypic leukemia, the 1-year overall and leukemia-free survival rates were 75±10% versus 50±13%, respectively (P=0."	2.79	Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial. ( Bilger, K; Blaise, D; Chevallier, P; de La Tour, RP; Delaunay, J; El-Cheikh, J; Furst, S; Guillaume, T; Labopin, M; Lioure, B; Michallet, M; Milpied, N; Mohty, M; Moreau, P; Socié, G; Tabrizi, R; Vigouroux, S, 2014)
" Our data suggest that a phase II trial should incorporate CPX-351 120 U/m(2) × 3 dosing on schedule B."	2.78	A phase I study of CPX-351 in combination with busulfan and fludarabine conditioning and allogeneic stem cell transplantation in adult patients with refractory acute leukemia. ( Christos, P; Feldman, E; Gergis, U; Mark, T; Mayer, S; McKenna, M; Pearse, R; Ritchie, E; Roboz, G; Scandura, J; Shore, T; van Besien, K; Wissa, U, 2013)
"Stomatitis was the most frequent toxicity in both trials."	2.78	Dose escalation of total marrow irradiation with concurrent chemotherapy in patients with advanced acute leukemia undergoing allogeneic hematopoietic cell transplantation. ( Forman, S; Liu, A; Palmer, J; Radany, E; Rosenthal, J; Schultheiss, T; Somlo, G; Stein, A; Wong, JY, 2013)
" We sought to determine the safety of GO in combination with busulfan/cyclophosphamide (Bu/Cy) conditioning before allogeneic hematopoietic stem cell transplantation (alloSCT)."	2.77	A Phase I study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophosphamide (Bu/Cy) and allogeneic stem cell transplantation in children with poor-risk CD33+ AML: a new targeted immunochemotherapy myeloablative conditioning (MAC) regim ( Baxter-Lowe, LA; Bhatia, M; Cairo, MS; Dela Cruz, F; Duffy, D; Foley, S; Garvin, JH; George, D; Hawks, R; Jin, Z; Le Gall, J; Morris, E; Satwani, P; Schwartz, J; van de Ven, C, 2012)
"Busulfan has a narrow therapeutic range, and in children, pharmacokinetic variability has been found to be high even after the use of intravenous (i."	2.77	Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling. ( Ahn, HS; Han, EJ; Jang, IJ; Jang, MK; Kang, HJ; Kim, H; Kim, NH; Lee, JW; Lee, SH; Park, KD; Shin, HY; Song, SH; Yu, KS; Yuk, YJ, 2012)
" Multivariate analysis (MVA) identified comorbidity score (HCT-CI) >2 and advanced disease as adverse factors with no independent impact of regimen."	2.77	Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity. ( Danylesko, I; Nagler, A; Shem-Tov, N; Shimoni, A; Volchek, Y; Yerushalmi, R, 2012)
"The optimal pretransplant regimen for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in patients ≥ 55 years of age remains to be determined."	2.76	Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life. ( Alatrash, G; Andersson, BS; Champlin, RE; Chiattone, A; de Lima, M; de Padua Silva, L; Giralt, SA; Hamerschlak, N; Hosing, C; Kebriaei, P; Kerbauy, F; Nieto, Y; Pelosini, M; Qazilbash, MH; Rondon, G; Saliba, RM; Wang, X; Xiao, L; Zhang, W, 2011)
" Reduced-intensity allogeneic SCT may offer a less toxic approach to patients with AML."	2.71	Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia. ( Bhatia, M; Bradley, B; Cairo, MS; Cooney, E; Del Toro, G; Foley, S; Garvin, J; George, D; Harrison, L; Hawks, R; Militano, O; Roman, E; Satwani, P; Unal, E; van de Ven, C; Wolownik, K, 2005)
"Cladribine (2-CdA) is a purine analogue that exhibits activity against a variety of hematological malignancies and has a potent immunosuppressive effect."	2.70	Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma. ( Kami, M; Kanai, S; Kanda, Y; Kato, K; Kawano, Y; Makimoto, A; Matsubara, H; Mineishi, S; Nakai, K; Ogasawara, T; Ohnishi, T; Saito, T; Shoji, N; Takaue, Y; Tanosaki, R; Tobinai, K; Wakasugi, H, 2002)
"Thiotepa (TTP) is an alkylating agent that has been used mainly in breast and ovarian cancer with 20-50% response rates."	2.69	The role of thiotepa in autologous bone marrow transplantation for acute leukemia. ( Finlander, R; Nagler, A; Naparstek, E; Or, R; Slavin, S; Varadi, G, 1998)
" The aim of this study was to determine the appropriate dosing of etoposide in combination with busulfan and cyclophosphamide in this setting."	2.69	Hematopoietic stem cell transplantation (HSCT) with a conditioning regimen of busulfan, cyclophosphamide, and etoposide for children with acute myelogenous leukemia (AML): a phase I study of the Pediatric Blood and Marrow Transplant Consortium. ( Coppes, MJ; Gamis, A; Hagg, R; Kamani, N; Mustafa, MM; Sandler, ES; Wall, D, 2000)
" Administration of busulfan as crushed rather than whole tablets reduced the delay time for appearance of busulfan in plasma but had no effect on absorption or other pharmacokinetic parameters."	2.67	Busulfan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia. ( Brian, RJ; Earl, JW; Scharping, CE; Shaw, PJ, 1994)
"Current intensive chemotherapy for acute nonlymphoblastic leukemia (ANLL) results in a complete remission in the majority of patients."	2.67	Busulfan/etoposide--initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with acute nonlymphoblastic leukemia. ( Amylon, MD; Blume, KG; Chao, NJ; Forman, SJ; Long, GD; Negrin, RS; Stein, AS; Wong, RM, 1993)
"One hundred twenty-seven patients with acute myelocytic leukemia (AML) were given busulfan 4 mg/kg on each of 4 days and cyclophosphamide 60 mg/kg on each of 2 days (BuCy2) followed by allogeneic bone marrow transplantation from an HLA-identical or one antigen disparate sibling."	2.67	Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2. ( Atkinson, K; Avalos, BR; Biggs, JC; Copelan, EA; Crilley, P; Cunningham, I; Kapoor, N; Klein, JP; Szer, J; Thompson, JM, 1991)
"Etoposide has also been tested in a wide range of combination regimens, but for many of these combinations, relatively few patients are included, and some combinations have only been tested in patients who have undergone autologous transplants."	2.48	High-dose etoposide in allogeneic stem cell transplantation. ( Ahmed, AB; Bruserud, O; Hatfield, KJ; Kittang, AO; Reikvam, H; Sjo, M; Tvedt, TH, 2012)
" Bypassing the oral route to achieve 100% bioavailability translated into improved control over drug administration, with increased safety and reliability of generating therapeutic Bu levels, maximizing antileukemic efficacy."	2.45	Busulfan in hematopoietic stem cell transplantation. ( Andersson, BS; Ciurea, SO, 2009)
"Leukemic cells from many patients with acute myelogenous leukemia (AML) have surface receptors for CSFs and may proliferate in response to CSFs."	2.40	Cytokine therapy for hematological malignancies. ( Ezaki, K; Tsuzuki, M, 1997)
"The technique of high-dose chemotherapy and bone-marrow transplantation takes advantage of any potential dose-response effect in the treatment of cancer and the ability of infused marrow to circumvent severe myelotoxicity."	2.38	High-dose chemotherapy with busulphan and cyclophosphamide and bone-marrow transplantation for drug-sensitive malignancies in adults: a preliminary report. ( Boyd, AW; Brodie, GN; Green, MD; Griffiths, JD; McGrath, KM; Russell, DM; Scarlett, JD; Sheridan, WP; Thomas, RJ; Vaughan, SL, 1989)
"For acute lymphoblastic leukemia (ALL) patients, total body irradiation (TBI)- based conditioning regimens are the first choice specially in young population."	1.91	Thiotepa, busulfan and fludarabine conditioning-regimen is a promising approach for older adult patients with acute lymphoblastic leukemia treated with allogeneic stem cell transplantation. ( Banet, A; Bazarbachi, A; Belhocine, R; Bonnin, A; Brissot, E; Duléry, R; El-Cheikh, J; Genthon, A; Labopin, M; Ledraa, T; Legrand, O; Malard, F; Memoli, M; Mohty, M; Sestili, S; Stocker, N; Van de Wyngaert, Z, 2023)
" Here, we compared post-transplant outcomes after individualized versus fixed busulfan dosage in intermediate-risk AML who achieved CR prior to allograft focusing on pre-transplant flow-MRD."	1.91	Individualized busulfan dosing improves outcomes compared to fixed-dose administration in pre-transplant minimal residual disease-positive acute myeloid leukemia patients with intermediate-risk undergoing allogeneic stem cell transplantation in CR. ( Ayuk, F; Bacher, U; Badbaran, A; Dadkhah, A; Freiberger, P; Janson, D; Klyuchnikov, E; Kröger, N; Langebrake, C; Massoud, R; Wolschke, C, 2023)
"Total body irradiation (TBI) at a dose of 12 Gy combined with cyclophosphamide (CyTBI12Gy) is one of the standard myeloablative regimens for patients with acute myeloid leukemia (AML) treated with allogeneic hematopoietic cell transplantation (allo-HCT)."	1.91	Fludarabine versus cyclophospamide in combination with myeloablative total body irradiation as conditioning for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study from the Acute Leukemia Working Party ( Arat, M; Bourhis, JH; Cornelissen, JJ; Giebel, S; Grillo, G; Hilgendorf, I; Kröger, N; Labopin, M; Maertens, J; Mohty, M; Nagler, A; Poiré, X; Salmenniemi, U; Savani, B; Schroeder, T; Spyridonidis, A; Swoboda, R, 2023)
"In conclusion, ATG and PTCy combined with Flu-based increased intensity conditioning regimen is effective for acute leukemia in children."	1.91	Intensified conditioning regimen with fludarabine combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in children with high-risk acute leukemia. ( Cao, J; Chen, D; Li, S; Liu, X; Lu, Y; Pei, R; Wang, T; Xu, X; Ye, P; Zheng, ZZ, 2023)
" The prediction of transplantation-related mortality (TRM) using the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) score and an arbitrary upper age limit of 55 years for administering myeloablative conditioning (MAC) are common strategies to ensure a safe procedure."	1.91	Myeloablative Dose of Busulfan and Fludarabine Combined with In Vivo T Cell Depletion Is Safe and Effective Conditioning for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients. ( Alshehri, H; Anteh, S; Avenoso, D; Bourlon, C; Bouziana, S; Dazzi, F; de Farias, M; Dragoi, OD; Gameil, A; Hannah, G; Kenyon, M; Krishnamurthy, P; Kulasekararaj, A; Leung, YT; Mehra, V; Pagliuca, A; Potter, V; Serpenti, F; Shah, MN; Slonim, LB; Wood, H, 2023)
"We prospectively studied clofarabine-fludarabine-busulfan (CloFluBu)-conditioning in allogeneic hematopoietic cell therapy (HCT) for lymphoid and myeloid malignancies and hypothesized that CloFluBu provides a less toxic alternative to conventional conditioning regimens, with adequate antileukemic activity."	1.72	Clofarabine-fludarabine-busulfan in HCT for pediatric leukemia: an effective, low toxicity, TBI-free conditioning regimen. ( Bierings, M; Boelens, JJ; Bresters, D; de Koning, CCH; Kollen, WJ; Lankester, AC; Lindemans, CA; Nierkens, S; Versluijs, AB, 2022)
"In patients with acute myelogenous leukemia (AML) (HRD, n = 16; MUD, n = 16), the 3-year GRFS, LFS, and OS rates in the HRD and MUD groups were 80."	1.72	Post-Transplantation Cyclophosphamide-Based Haploidentical versus Matched Unrelated Donor Peripheral Blood Hematopoietic Stem Cell Transplantation Using Myeloablative Targeted Busulfan-Based Conditioning for Pediatric Acute Leukemia. ( An, HY; Choi, JY; Hong, KT; Kang, HJ; Kim, BK; Park, HJ, 2022)
"Optimal conditioning for adults with acute lymphoblastic leukemia (ALL) treated with haploidentical hematopoietic cell transplantation (haplo-HCT) and post-transplant cyclophosphamide has not been established so far."	1.72	Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia W ( Aljurf, M; Angelucci, E; Arat, M; Bernasconi, P; Giebel, S; Labopin, M; Mohty, M; Nagler, A; Pavlu, J; Peric, Z; Pioltelli, P; Rigacci, L; Risitano, A; Rovira, M; Saccardi, R; Savani, BN; Sica, S; Socié, G; Spyridonidis, A; Swoboda, R; Tischer, J; Van Gorkom, G; Vitek, A, 2022)
"We compared transplant outcomes of 708 acute myeloid leukemia (AML) patients receiving haploidentical allogeneic hematopoietic-cell transplantation using thiotepa/busulfan/fludarabine (TBF) conditioning with posttransplant cyclophosphamide (ptCy), to 2083 patients receiving matched unrelated donor (MUD) transplantation using fludarabine/busulfan (FB) conditioning and in vivo T-cell depletion."	1.62	Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia. ( Angelucci, E; Bazarbachi, A; Berceanu, A; Blaise, D; Bulabois, CE; Ceballos, P; El Cheikh, J; Forcade, E; Kröger, N; Labopin, M; Mielke, S; Mohty, M; Nagler, A; Rambaldi, A; Savani, B; Socié, G; Spyridonidis, A; Yakoub-Agha, I, 2021)
"Outcomes were compared in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome who received either myeloablative, fractionated busulfan (f-Bu) dosed to achieve an area under the curve of 20,000 μmol per minute (f-Bu20K) over 2 weeks (n = 84) or a standard, nonfractionated, lower busulfan dose regimen of 16,000 μmol per minute (Bu16K) over 4 days (n = 78)."	1.62	Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndrome. ( Alousi, AM; Andersson, BS; Bashir, Q; Champlin, RE; Chen, J; Ciurea, SO; Hosing, C; Kebriaei, P; Marin, D; Mehta, RS; Olson, AL; Oran, B; Popat, UR; Rezvani, K; Saliba, RM; Shpall, EJ; Valdez, BC, 2021)
"Busulfan was considered the cause in the first reported case because the transgene was not present in the AML/MDS."	1.62	Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both, or neither. ( DeBaun, MR; Jones, RJ, 2021)
"Primary refractory acute myeloid leukemia (AML) is associated with dismal prognosis."	1.56	Tandem Allogeneic Hematopoietic Stem Cell Transplantation for Salvage Treatment of Acute Myeloid Leukemia Refractory to Induction Chemotherapy: A Case Report. ( Basak, GW; Drozd-Sokolowska, J; Dwilewicz-Trojaczek, J; Gierej, B; Halaburda, K; Karakulska-Prystupiuk, E; Sachs, W; Tormanowska, M; Urbanowska, E; Wiktor-Jedrzejczak, W, 2020)
"We analyzed 257 patients with acute myeloid leukemia (AML) who received allogeneic stem cell transplantation (SCT) and fulfilled the following criteria: intermediate- or poor-risk disease by National Comprehensive Cancer Network guidelines (2017, version 3), in first complete remission (CR1) at SCT, received either myeloablative conditioning (MAC; busulfan plus cyclophosphamide or cyclophosphamide plus total body irradiation) or reduced-intensity conditioning (RIC; FluBu2TBI400) peripheral blood SCT from 8/8 matched sibling or unrelated donor, and having bone marrow Wilms tumor gene 1 (WT1) expression results before transplant."	1.56	Comparison of Myeloablative (CyTBI, BuCy) versus Reduced-Intensity (FluBu2TBI400) Peripheral Blood Stem Cell Transplantation in Acute Myeloid Leukemia Patients with Pretransplant Low WT1 Expression. ( Cho, BS; Cho, SG; Eom, KS; Jeon, YW; Kim, DW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, GJ; Park, S; Park, SS; Shin, SH; Yahng, SA; Yoon, JH, 2020)
" The RIC and MAC regimens were dosed at the average daily area under the concentration-vs-time curve (AUC) of 4000 µMol min and 5000-6000 µMol min, or total course AUC of 16,000 µMol min and 20,000-24,000 µMol min, respectively; PK-guided dosing removes overlap in systemic Bu exposure."	1.51	Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS. ( Alatrash, G; Andersson, BS; Champlin, RE; Chen, J; Crain, AK; Di Stasi, A; Jones, RB; Kidwell, KM; Popat, U; Shpall, EJ; Thall, PF; Zope, M, 2019)
"Primary refractory acute myeloid leukemia (AML) is associated with a dismal prognosis."	1.51	Sequential therapy for patients with primary refractory acute myeloid leukemia: a historical prospective analysis of the German and Israeli experience. ( Amit, O; Avivi, I; Chemnitz, JM; Hallek, M; Holtick, U; Moshe, Y; Ram, R; Scheid, C; Wolf, D, 2019)
"Approximately 30-40% of patients with acute myeloid leukemia (AML) experience induction failures."	1.48	Clofarabine followed by haploidentical stem cell transplant using fludarabine, busulfan, and total-body irradiation with post-transplant cyclophosphamide in non-remission AML. ( Claxton, D; Miki, K; Mineishi, S; Naik, S; Rakszawski, K; Shike, H; Wagner, H, 2018)
" There is still an important variation in Bu pharmacokinetic between patients that is associated with an increased risk of toxicity and graft failure."	1.48	Pharmacokinetics-adapted Busulfan-based myeloablative conditioning before unrelated umbilical cord blood transplantation for myeloid malignancies in children. ( Ansari, M; Benadiba, J; Bittencourt, H; Cellot, S; Duval, M; Krajinovic, M; Teira, P; Vachon, MF, 2018)
"Twenty patients with primary acute myeloid leukemia had been randomized into busulfan/fludarabine and modified busulfan/cyclophosphamide groups."	1.48	Comparison of Different Conditioning Regimens of Haploidentical Hematopoietic Stem Cell Transplant in Patients With Acute Myeloid Leukemia. ( Fang, X; Jiang, Y; Li, Y; Liu, X; Sui, X; Wang, X; Xu, H; Zhang, L, 2018)
"We compared outcomes of de-novo acute myeloid leukemia patients in complete remission receiving NTD-Haplo (n = 186) vs."	1.48	Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine. ( Angelucci, E; Arcese, W; Baron, F; Benedetto, B; Blaise, D; Carella, MA; Giannotti, F; Labopin, M; Mohty, M; Nagler, A; Rambaldi, A; Rocha, V; Ruggeri, A; Saccardi, R; Santarone, S; Santasusana, JR; Sanz, J; Shouval, R; Sierra, J, 2018)
" Moreover, it appears to be safe with a low NRM rate among high-risk patients."	1.43	The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m(2) intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myel ( Blaise, D; Calmels, B; Castagna, L; Chabannon, C; Crocchiolo, R; Devillier, R; El-Cheikh, J; Faucher, C; Furst, S; Granata, A; Harbi, S; Lemarie, C; Vey, N; Wanquet, A; Weiller, PJ, 2016)
" Pharmacokinetic dosing of busulfan (Bu) is frequently done for myeloablative conditioning, but evidence for its use is limited in RIC transplants."	1.43	Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine-Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic Dosing. ( Al-Kali, A; Alkhateeb, HB; Damlaj, M; Gangat, N; Gastineau, DA; Hashmi, S; Hefazi, M; Hogan, WJ; Litzow, MR; Partain, DK; Patnaik, MM; Wolf, RC, 2016)
"busulfan (Bu) has been shown to be highly effective as a pretransplant conditioning regimen in acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and myelodysplastic syndrome (MDS)."	1.43	Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome. ( Alatrash, G; Alousi, AM; Andersson, BS; Champlin, RE; Chen, J; de Lima, M; Fox, PS; Garber, HR; Hosing, C; Janbey, S; Jones, RB; Kebriaei, P; Ning, J; Popat, U; Rondon, G; Shpall, EJ; Thall, PF; Valdez, BC; Worth, LL, 2016)
"Pediatric patients with acute myeloid leukemia (AML) mainly receive myeloablative conditioning regimens based on busulfan (BU) or total body irradiation (TBI) before allogeneic hematopoietic cell transplantation (allo-HCT); however, the optimal conditioning regimen remains unclear."	1.42	Comparison of Outcomes for Pediatric Patients With Acute Myeloid Leukemia in Remission and Undergoing Allogeneic Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Based on Either Intravenous Busulfan or Total Body Irradiation: A ( Adachi, S; Atsuta, Y; Goto, H; Inagaki, J; Inoue, M; Ishida, H; Kato, K; Kato, M; Kawano, Y; Koh, K; Kudo, K; Miyamura, T; Ogawa, A; Sawada, A; Taga, T; Terui, K; Tomizawa, D; Yamashita, T, 2015)
"Busulfan is a commonly used chemotherapeutic agent in myeloablative conditioning regimens for allogeneic hematopoietic cell transplantation (allo-HCT)."	1.42	Subacute hepatic necrosis mimicking veno-occlusive disease in a patient with HFE H63D homozygosity after allogeneic hematopoietic cell transplantation with busulfan conditioning. ( Boyer, MW; Chen, S; Chen, X; Hildebrandt, GC; McDonald, GB; Osborn, JD, 2015)
"Curcumin (CUR) has received considerable attention as a result of its anticancer activity in leukemia and solid tumors."	1.42	Curcumin Enhanced Busulfan-Induced Apoptosis through Downregulating the Expression of Survivin in Leukemia Stem-Like KG1a Cells. ( Fan, J; Guo, K; Huang, J; Weng, G; Zeng, Y, 2015)
"We exposed the acute myeloid leukemia (AML) cell lines KBM3/Bu250(6) and OCI-AML3 to Flu, Clo, Bu and SAHA alone and in various combinations."	1.40	The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan. ( Andersson, BS; Champlin, RE; Corn, P; Dominguez, JR; Li, Y; Song, G; Valdez, BC, 2014)
" In an effort to minimize these adverse effects, we conducted bone marrow transplantation (BMT) from unrelated volunteer donors using a conditioning regimen without BU or TBI."	1.40	Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia. ( Kato, K; Matsumoto, K; Matsuyama, T; Yoshida, N, 2014)
" busulfan dosing (total dose 3."	1.39	Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia. ( Alyea, EP; Antin, JH; Armand, P; Attar, EC; Ballen, KK; Chen, YB; Coughlin, E; Cutler, C; Dey, BR; Ho, VT; Kennedy, KF; Koreth, J; McAfee, SL; Soiffer, RJ; Spitzer, TR, 2013)
"Lower dosage of total body irradiation (TBI) and chemotherapy in reduced-intensity conditioning (RIC) regimens prior to allogeneic stem cell transplantation have reduced the toxicity of the conditioning and non-relapse mortality."	1.38	Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia. ( Brossart, P; Chemnitz, JM; Hallek, M; Holtick, U; Krause, A; Scheid, C; Shimabukuro-Vornhagen, A; Theurich, S; von Lilienfeld-Toal, M, 2012)
" In search of less toxic alternatives, we hypothesized that combination of busulfan (Bu), fludarabine (Flu) and clofarabine (Clo) would provide superior efficacy."	1.37	The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling. ( Andersson, BS; Champlin, RE; Li, Y; Murray, D; Valdez, BC, 2011)
"We used pharmacokinetic (PK) targeting of BU in 145 consecutive patients treated with fludarabine and i."	1.37	Pharmacokinetic targeting of i.v. BU with fludarabine as conditioning before hematopoietic cell transplant: the effect of first-dose area under the concentration time curve on transplant-related outcomes. ( Anasetti, C; Ayala, E; Fancher, K; Fernandez, H; Field, T; Gardiner, JA; Kharfan-Dabaja, MA; Kim, J; Miller, S; Milone, MC; Perez, L; Perkins, J; Shaw, LM; Tate, C, 2011)
"Busulfan is a bifunctional alkylating agent widely used in pretransplant conditioning regimens in patients undergoing stem cell transplantation for hematologic malignancies."	1.37	Busulfan and metronidazole: an often forgotten but significant drug interaction. ( Andersson, BS; Culotta, KS; Gulbis, AM; Jones, RB, 2011)
"The patient was a 17-year-old male with acute myeloid leukemia in second complete remission."	1.36	[Usefulness of serum plasminogen activator inhibitor-1 for diagnosis and monitoring of late-onset sinusoidal obstruction syndrome after allogeneic stem cell transplantation]. ( Fujita, H; Ishigatsubo, Y; Ito, S; Kato, J; Nakaya, A; Ohata, M; Sano, A; Tachibana, T; Taguchi, J; Takemura, S, 2010)
"Oral lorazepam was tolerated by the patients, but all patients needed dose reduction due to some adverse effects."	1.36	Oral lorazepam prevents seizure during high-dose busulfan in children undergoing hematopoietic stem cell transplantation: a prospective study. ( Amini, M; Ghavamzadeh, A; Hadjibabaie, M; Hamedani, R; Hamidieh, AA; Sadrai, S, 2010)
" We retrospectively compared outcomes of a consecutive series of 51 AML patients treated with oral busulfan (1 mg/kg every 6 hours for 4 days) and cyclophosphamide (60 mg/kg IV × 2 days) - (Bu/Cy) with 100 consecutive AML patients treated with pharmacokinetic targeted IV busulfan (AUC < 6000 μM/L*min per day × 4 days) and fludarabine (40 mg/m2 × 4 days) - (t-IV Bu/Flu)."	1.36	Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia. ( Anasetti, C; Fernandez, HF; Field, T; Kharfan-Dabaja, MA; Kim, J; Nishihori, T; Perez, L; Perkins, J; Pidala, J, 2010)
"Busulfan was quantitated using ultraviolet absorbance detection after derivatization and HPLC separation."	1.32	Plasma pharmacokinetics of high-dose oral busulfan in children and adults undergoing bone marrow transplantation. ( Blazar, B; Bostrom, B; Bruns, A; Enockson, K; Johnson, A, 2003)
"The prognosis for DS acute myeloid leukemia (AML) is better than for non-DS AML, but the clinical outcome of DS acute lymphoblastic leukemia (ALL) is equal to that of non-DS ALL."	1.31	Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. ( Creutzig, U; de Vries, E; Hählen, K; Huismans, DR; Janka-Schaub, GE; Jansen, G; Kaspers, GJ; Peters, GJ; Pieters, R; Rots, MG; van Zantwijk, CH; Veerman, AJ; Zwaan, CM, 2002)
"Fifty patients with acute myeloid leukemia (AML) or chronic myeloid leukemia (CML) underwent allogeneic bone marrow transplantation between October 1988 and January 1997."	1.30	Busulfan, cyclophosphamide and total body irradiation as conditioning for allogeneic bone marrow transplantation for acute and chronic myeloid leukemia. ( Goto, S; Hirabayashi, N; Ishii, M; Mitsuma, A; Noda, N; Yuge, M, 1998)
"Diagnoses included acute myelogenous leukemia (n = 20), acute lymphoblastic leukemia (n = 8) and chronic myelogenous leukemia (n = 2)."	1.30	Allogeneic bone marrow transplantation for childhood leukemia following a busulfan and melphalan preparative regimen. ( Kato, K; Kojima, S; Matsuyama, T, 1998)
"Busulfan is a carcinostatic which is used for myelocytic leukemia."	1.30	Cataract induced by short-term administration of large doses of busulfan: a case report. ( Amemiya, T; Kaida, T; Ogawa, T, 1999)
"Fourteen patients with acute nonlymphoblastic leukemia (ANLL) (n = 13) or juvenile chronic myelomonocytic leukemia (n = 1) were transplanted after conditioning with high-dose busulfan (4 mg/kg daily on days -7 to -4) and melphalan (180 mg/m2 on day -2)."	1.29	High-dose busulfan and melphalan before bone marrow transplantation for acute nonlymphoblastic leukemia. ( Badell, I; Brunet, S; Cubells, J; Domingo-Albós, A; Martino, R; Sureda, A; Torras, A, 1995)
"This high risk of relapse is not observed when the dose of cyclophosphamide is increased to 200 mg/kg."	1.29	Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: impact of conditioning regimen without total-body irradiation--a report from the Société Française de Greffe de Moelle. ( Bernaudin, F; Blaise, D; Bordigoni, P; Esperou-Bourdeau, H; Gluckman, E; Jouet, JP; Michel, G; Pico, JL; Reiffers, J; Thuret, I, 1994)
"Clonal chromosome aberrations observed in patients who have relapsed after autologous bone marrow transplantation (ABMT) are usually related to the cytogenetic abnormalities observed at diagnosis."	1.29	Detection of occasional and clonal chromosome aberrations in patients with acute non-lymphocytic leukemia after autologous bone marrow transplantation. ( Gherlinzoni, F; Manfroi, S; Mangianti, S; Martinelli, G; Miggiano, MC; Pelliconi, S; Testoni, N; Tura, S; Visani, G; Zaccaria, A, 1996)
"Etoposide is one of the few drugs being used in conditioning regimens because of the ease with which its dosage can be escalated by a factor of 6 compared to the normal dose."	1.29	The pharmacokinetics and toxicity of two application schedules with high-dose VP-16 in patients receiving an allogeneic bone marrow transplantation. ( Bewermeier, P; Hossfeld, DK; Kruger, W; Mross, K; Reifke, J; Zander, A, 1996)
"Leukemic blast progenitors in acute myeloblastic leukemia (AML) undergo terminal divisions and/or self-renewal, which can be studied by the methylcellulose culture method and suspension culture, respectively."	1.28	Comparative effects of busulfan, cytosine arabinoside and adriamycin on different maturation stages of normal human bone marrow cells. ( Nagata, K; Nara, N; Suzuki, T; Tohda, S, 1990)
"No other relapses have been seen, with one second remission patient remaining leukaemia-free at 24 months, and six first remission patients in continuing remission 11 to 23 (median 20) months post transplant."	1.28	Autologous bone marrow transplantation for acute myeloid leukaemia in remission: a preliminary report. ( Bradstock, KF; Castaldi, PA; Hughes, WG; Kabral, A; Koutts, J; Lee, CH; Posen, J; Robertson, TI, 1990)
"Twenty-five consecutive patients with acute myelogenous leukemia (AML) underwent 26 allogeneic bone marrow transplants at Hahnemann University Hospital."	1.28	Bone marrow transplantation following busulfan and cyclophosphamide for acute myelogenous leukemia. ( Bigler, R; Brodsky, I; Bulova, S; Crilley, P; Topolsky, D, 1990)
"A patient with acute myeloblastic leukemia received high-dose busulfan (1 mg/kg by mouth every 6 h for 4 days) as myelo-ablative therapy for autologous bone marrow transplantation."	1.28	Cerebrospinal fluid and plasma concentrations of busulfan during high-dose therapy. ( Ehrsson, H; Hassan, M; Oberg, G; Simonsson, B; Smedmyr, B; Tötterman, T; Wallin, I, 1989)
"Ninety-nine patients with acute nonlymphocytic leukemia (ANLL) received HLA-identical bone marrow transplants (BMTs) from sibling donors after preparation with high doses of busulfan and cyclophosphamide."	1.28	Allogeneic bone marrow transplantation after high-dose busulfan and cyclophosphamide in patients with acute nonlymphocytic leukemia. ( Ambinder, RF; Beschorner, WB; Braine, HG; Burns, WH; Geller, RB; Piantadosi, S; Saral, R; Vogelsang, GB; Wingard, JR; Zahurak, M, 1989)
" Mean elimination half-life in plasma was 2."	1.28	Pharmacokinetic and metabolic studies of high-dose busulphan in adults. ( Ehrnebo, M; Ehrsson, H; Eksborg, S; Hassan, M; Oberg, G; Simonsson, B; Smedmyr, B; Tötterman, T; Wallin, I, 1989)
" To determine the drug-related nonhematologic toxic effects of this new regimen without confounding factors associated with allogeneic transplantation, we conducted a pilot study using this new regimen in 20 patients with acute myeloid leukemia (AML) in first remission prior to autologous unpurged marrow transplantation."	1.28	Acute toxicity and first clinical results of intensive postinduction therapy using a modified busulfan and cyclophosphamide regimen with autologous bone marrow rescue in first remission of acute myeloid leukemia. ( Beelen, DW; Graeven, U; Mahmoud, HK; Quabeck, K; Sayer, HG; Schaefer, UW, 1989)
"14 patients with essential thrombocythemia (ET) and 1 patient with agnogenic myeloid metaplasia received (1-(2-chloroethyl)-cyclohexyl-nitrosourea (CCNU), 80 mg/m2, p."	1.27	1-(2-Chloroethyl)-cyclohexyl-nitrosourea-induced remission in essential thrombocythemia. ( Grossi, A; Leoni, F; Rossi Ferrini, P, 1983)
"Five patients with acute myelocytic leukemia (AML) after combined modality therapy for Hodgkin's disease (HD) were treated with cyclophosphamide and busulfan followed by bone marrow transplantation (BMT)."	1.27	Successful marrow transplantation for acute myelocytic leukemia following therapy for Hodgkin's disease. ( Burns, WH; Geller, RB; Santos, GW; Saral, R; Vogelsang, GB; Wingard, JR; Yeager, AM, 1988)
"The presence of D group complex chromosomal abnormalities could be responsible for the simultaneous massive Pelger anomaly of granulocytes."	1.27	[Acute leukemia secondary to idiopathic myelofibrosis with homozygote pseudo-Pelger anomaly and complex chromosomal changes]. ( Bartolomei, P; Bortotto, L; Fossaluzza, V; Tosato, F, 1986)
"A patient with chronic myelocytic leukemia in whom a clinical and hematological remission occurred after a single course of busulfan is described."	1.26	A 13-years remission in chronic myelocytic leukemia after a single course of busulfan. ( Barabash, G; Benjamin, D; Djaldetti, M; Douer, D; Pinkhas, J; Weinberger, A, 1978)

Research

Studies (411)

Authors

Clinical Trials (28)

Trial Overview

Trial Outcomes

Cumulative Incidence of Chronic GVHD According to BMTCTN

Timeframe	Studies, this research(%)	All Research%
pre-1990	61 (14.84)	18.7374
1990's	56 (13.63)	18.2507
2000's	54 (13.14)	29.6817
2010's	154 (37.47)	24.3611
2020's	86 (20.92)	2.80

Authors	Studies
Kurosawa, S	2
Shimomura, Y	3
Itonaga, H	2
Najima, Y	2
Kobayashi, T	2
Ozawa, Y	5
Kanda, Y	5
Kako, S	3
Kawakita, T	4
Matsuoka, KI	3
Maruyama, Y	4
Ota, S	4
Nakazawa, H	2
Imada, K	2
Kanda, J	5
Fukuda, T	10
Atsuta, Y	12
Aoki, J	3
Shimoni, A	8
Robin, M	2
Iacobelli, S	2
Beelen, D	3
Mufti, GJ	4
Ciceri, F	5
Bethge, W	7
Volin, L	7
Blaise, D	20
Ganser, A	5
Luft, T	2
Chevallier, P	4
Schwerdtfeger, R	2
Koster, L	1
de Witte, T	2
Kröger, N	17
Nagler, A	38
Yakoub-Agha, I	11
Garcia, JS	1
Kim, HT	2
Murdock, HM	1
Cutler, CS	2
Brock, J	1
Gooptu, M	2
Ho, VT	4
Koreth, J	3
Nikiforow, S	2
Romee, R	1
Shapiro, R	1
Loschi, F	1
Ryan, J	1
Fell, G	1
Karp, HQ	1
Lucas, F	1
Kim, AS	1
Potter, D	1
Mashaka, T	1
Stone, RM	2
DeAngelo, DJ	1
Letai, A	1
Lindsley, RC	1
Soiffer, RJ	5
Antin, JH	3
O'Hagan Henderson, S	1
Frietsch, JJ	1
Hilgendorf, I	4
Hochhaus, A	1
Köhne, CH	1
Casper, J	5
Yeh, AC	1
O'Donnell, PV	1
Schoch, G	1
Martin, PJ	3
McFarland, C	1
McCune, JS	2
Cooper, JP	1
Doney, K	1
Flowers, MED	1
Sorror, ML	2
Appelbaum, FR	8
Storer, BE	5
Gooley, T	2
Deeg, HJ	9
Versluijs, AB	1
de Koning, CCH	1
Lankester, AC	1
Nierkens, S	1
Kollen, WJ	1
Bresters, D	1
Lindemans, CA	1
Boelens, JJ	2
Bierings, M	1
Hong, KT	1
Park, HJ	1
Kim, BK	2
An, HY	1
Choi, JY	1
Kang, HJ	2
Swoboda, R	5
Labopin, M	37
Giebel, S	11
Angelucci, E	5
Arat, M	5
Aljurf, M	5
Sica, S	2
Pavlu, J	3
Socié, G	17
Bernasconi, P	1
Rigacci, L	1
Tischer, J	6
Risitano, A	1
Rovira, M	3
Saccardi, R	2
Pioltelli, P	2
Van Gorkom, G	3
Vitek, A	1
Savani, BN	12
Spyridonidis, A	11
Peric, Z	3
Mohty, M	35
Pan, WY	1
Li, KX	1
Wu, HY	1
He, YZ	1
DU, JW	1
Zheng, YL	1
Tu, SF	1
Song, CY	1
Li, YH	1
Huang, YX	1
Valdez, BC	12
Murray, D	4
Yuan, B	1
Nieto, Y	6
Popat, U	12
Andersson, BS	25
Uemura, Y	1
Hirakawa, T	1
Matsunawa, M	1
Kozuki, K	1
Saiki, Y	1
Takimoto, M	1
Sano, F	1
Watanabe, K	1
Inoue, Y	1
Arai, A	1
Kimura, T	3
Ishiyama, K	2
Braitsch, K	1
Schwarz, A	1
Koch, K	1
Hubbuch, M	1
Menzel, H	1
Keller, U	1
Götze, KS	1
Bassermann, F	1
Herhaus, P	1
Verbeek, M	4
Rodríguez-Arbolí, E	2
Eder, M	2
Brecht, A	6
Blau, IW	2
Huynh, A	5
Forcade, E	5
Bondarenko, S	1
Bulabois, CE	2
Einsele, H	3
Stölzel, F	3
Savani, B	11
Bazarbachi, A	8
Brissot, E	4
Schmid, C	4
Thall, PF	10
Ma, J	1
Bassett, R	3
Chen, J	14
Ahmed, S	2
Alousi, A	4
Bashir, Q	6
Ciurea, S	3
Gulbis, A	2
Cool, R	2
Kawedia, J	2
Hosing, C	7
Kebriaei, P	10
Kornblau, S	1
Myers, A	1
Oran, B	6
Rezvani, K	3
Shah, N	1
Shpall, E	4
Parmar, S	2
Popat, UR	3
Champlin, RE	23
Beelen, DW	6
Stelljes, M	6
Reményi, P	1
Wagner-Drouet, EM	1
Dreger, P	4
Junghanß, C	1
Labussiere-Wallet, H	5
Schaefer-Eckart, K	3
Grigoleit, GU	1
Scheid, C	7
Patriarca, F	3
Rambaldi, A	9
Niederwieser, D	3
Russo, D	2
Holler, E	1
Glass, B	1
Wulf, G	1
Basara, N	1
Bieniaszewska, M	1
Stuhler, G	3
La Rocca, U	1
Finke, J	4
Benedetti, F	1
Pichlmeier, U	2
Klein, A	1
Baumgart, J	4
Markiewicz, M	2
Alatrash, G	5
Saberian, C	1
Ledesma, C	1
Lu, Y	3
Daher, M	1
Mehta, R	2
Olson, A	3
Anderlini, P	5
Marin, D	3
Alousi, AM	4
Shpall, EJ	9
Rondon, G	9
Qazilbash, M	1
Devillier, R	5
Galimard, JE	1
Raiola, AM	2
Castagna, L	5
Chalandon, Y	1
Martino, M	2
Bug, G	2
Bruno, B	6
Vrhovac, R	2
Charbonnier, A	2
Olivieri, A	3
Bay, JO	2
Arroyo, H	1
Avenoso, D	2
Neubauer, A	1
Nguyen, S	3
Zhang, H	3
Fan, Z	5
Huang, F	6
Han, L	1
Xu, Y	2
Xu, N	4
Deng, L	1
Wang, S	1
Lin, D	2
Luo, X	1
Zhang, Q	2
Liu, X	5
Li, X	4
Liang, X	3
Xie, S	1
Qu, H	2
Yu, S	2
Zhou, H	3
Shi, P	3
Xuan, L	4
Lin, R	4
Liu, H	9
Jin, H	3
Sun, J	6
Liu, Q	5
Pizzola, CJ	1
Cioccio, J	1
Rakszawski, KL	1
Nickolich, M	1
Ehmann, WC	1
Rybka, WB	1
Wirk, B	2
Naik, S	3
Zheng, H	1
Silar, B	1
Shike, H	2
Zhou, S	1
Mineishi, S	5
Minagawa, K	1
Claxton, DF	1
Meur, GL	1
Plesa, A	1
Larcher, MV	1
Fossard, G	1
Barraco, F	1
Loron, S	1
Balsat, M	1
Ducastelle-Leprêtre, S	1
Gilis, L	1
Thomas, X	1
Ghesquières, H	1
Tigaud, I	1
Hayette, S	1
Huet, S	1
Sujobert, P	1
Renault, M	1
Thérèse, RM	1
Michallet, M	7
Heiblig, M	1
Kawashiri, A	1
Nakagawa, SI	1
Ishiguro, C	1
Mochizuki, K	1
Maeda, Y	2
Kurokawa, T	1
Banet, A	1
Stocker, N	1
Duléry, R	1
Malard, F	2
Van de Wyngaert, Z	1
Genthon, A	1
Memoli, M	1
Legrand, O	1
Bonnin, A	1
Ledraa, T	1
Belhocine, R	1
Sestili, S	1
El-Cheikh, J	4
Klyuchnikov, E	1
Langebrake, C	1
Badbaran, A	1
Dadkhah, A	1
Massoud, R	1
Freiberger, P	1
Ayuk, F	2
Janson, D	1
Wolschke, C	1
Bacher, U	2
Connor, MP	1
Loren, AW	1
Hexner, EO	1
Martin, ME	1
Gill, SI	1
Luger, SM	1
Mangan, JK	1
Perl, AE	1
McCurdy, SR	1
Pratz, KW	1
Timlin, C	1
Freyer, CW	1
Carulli, A	1
Catania, C	1
Smith, J	1
Hollander, L	1
Zebrowski, AM	1
Stadtmauer, EA	1
Porter, DL	2
Frey, NV	1
Luo, C	1
Wu, G	1
Huang, X	1
Ding, Y	1
Huang, Y	3
Song, Q	1
Hou, Y	1
Xu, S	1
Choi, Y	1
Choi, EJ	1
Park, HS	1
Lee, JH	6
Lee, YS	2
Kang, YA	2
Jeon, M	2
Woo, JM	1
Kang, H	2
Baek, S	1
Kim, SM	1
Bong, CE	1
Lee, KH	3
Truscott, L	3
Pariury, H	3
Hanmod, S	3
Davini, M	3
de la Maza, M	3
Sapp, LN	3
Staples, K	3
Proytcheva, M	3
Katsanis, E	3
Halahleh, KA	3
Ma'koseh, M	3
Sultan, I	3
Rimawi, DH	3
Muradi, I	3
Gale, RP	4
Schroeder, T	5
Hamladji, RM	6
Potter, V	6
Berceanu, A	4
Ozdogu, H	7
Sanz, J	6
Zhang, Y	4
Wu, M	2
Sun, Z	2
Xiong, Y	1
Xu, J	1
Wang, Z	2
Maertens, J	4
Bourhis, JH	2
Grillo, G	1
Salmenniemi, U	1
Poiré, X	3
Cornelissen, JJ	3
Dai, M	1
Jiang, E	3
Wang, Y	3
Nie, D	3
Chen, H	2
Ye, J	1
Yan, C	1
Han, M	3
Hama, A	1
Taga, T	2
Tomizawa, D	2
Muramatsu, H	2
Hasegawa, D	3
Adachi, S	3
Yoshida, N	3
Noguchi, M	2
Sato, M	1
Okada, K	1
Koh, K	4
Mitsui, T	1
Takahashi, Y	1
Miyamura, T	3
Hashii, Y	2
Kato, K	6
Okamoto, Y	2
Shibata, S	1
Arai, Y	2
Kondo, T	6
Mizuno, S	3
Harada, K	1
Miyakoshi, S	3
Uchida, N	7
Eto, T	7
Katsuoka, Y	1
Matsue, K	3
Nishiwaki, K	1
Takada, S	1
Doki, N	2
Itoh, M	1
Nagafuji, K	3
Tanaka, J	1
Yanada, M	4
Tang, Y	2
Zhang, Z	1
Liu, S	1
Yao, Y	1
Pan, T	1
Qi, J	1
Liu, Y	4
Cai, C	1
Zhou, M	1
He, X	1
Hu, X	1
Ma, X	1
Wu, D	4
Han, Y	1
Niittyvuopio, R	1
Reinhardt, HC	1
Kaare, A	1
Schäfer-Eckart, K	2
Mielke, S	2
Carlson, K	1
Hirschbühl, K	1
Polge, E	8
Bonnet, S	1
Ling, Y	1
Guo, Z	1
Xu, X	2
Liu, C	1
Ou, R	1
Zhai, X	2
Zhao, Y	1
Cao, J	1
Wang, T	1
Chen, D	1
Li, S	3
Ye, P	1
Zheng, ZZ	1
Pei, R	1
Cassanello, G	1
Serpenti, F	2
Bagnoli, F	1
Saporiti, G	2
Goldaniga, M	1
Cavallaro, F	1
Barbullushi, K	1
Bellani, V	1
Galassi, G	1
Onida, F	2
Tefferi, A	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Study of Venetoclax and Reduced-intensity Conditioning Regimen(RIC) for Allogeneic Stem Cell Transplantation(Allo-HSCT) in Elderly Patients With High-risk Myeloid Malignancies[NCT05583175]	Phase 2	50 participants (Anticipated)	Interventional	2022-11-01	Recruiting
A Phase 1 Study of Adding Venetoclax to a Reduced Intensity Conditioning Regimen and to Maintenance in Combination With a Hypomethylating Agent After Allogeneic Hematopoietic Cell Transplantation for Patients With High Risk AML, MDS, and MDS/MPN Overlap S[NCT03613532]	Phase 1	78 participants (Anticipated)	Interventional	2018-10-24	Recruiting
Busulfan Plus Cyclophosphamide vs Total Body Irradiation Plus Cyclophosphamide Conditioning Regimen for Standard-risk Acute Lymphocytic Leukemia Undergoing HLA-matched Allogeneic Hematopoietic Stem Cell Transplantation[NCT02670252]	Phase 3	550 participants (Actual)	Interventional	2016-01-31	Completed
Intensive Conditioning Regimen With Thiotepa Combined With Busulfan, Fludarabine and Cytarabine for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Myeloid Malignancies With Extramedullary Involvement[NCT06111612]		50 participants (Anticipated)	Observational	2024-01-01	Not yet recruiting
Reduced Intensity Conditioning With Fludarabine and Busulfan Versus Fludarabine and Melphalan Before Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Randomised, Single-Center, Phase III Study[NCT05674539]	Phase 3	200 participants (Anticipated)	Interventional	2022-12-28	Recruiting
Decitabine Followed by Bone Marrow Transplant and High-Dose Cyclophosphamide for the Treatment of Relapsed and Refractory Acute Myeloid Neoplasms[NCT01707004]	Phase 2	20 participants (Actual)	Interventional	2013-05-16	Completed
A Phase 1/2 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With the LentiGlobin BB305 Lentiviral Vector in Subjects With Severe Sickle Cell Disease[NCT02140554]	Phase 1/Phase 2	50 participants (Anticipated)	Interventional	2014-08-31	Active, not recruiting
Allogeneic Hematopoietic Cell Transplant for Hematological Cancers and Myelodysplastic Syndromes in HIV-Infected Individuals (BMT CTN #0903)[NCT01410344]	Phase 2	20 participants (Actual)	Interventional	2011-09-30	Completed
A Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia (BMT CTN #0901)[NCT01339910]	Phase 3	272 participants (Actual)	Interventional	2011-06-30	Terminated (stopped due to Accrual terminated as recommended by the data and safety monitoring board.)
A Phase II Open-label, Multicenter, Non Randomized Study Evaluating the Efficacy and the Safety of Clofarabine in Combination With IV Busulfan and Thymoglobulin (CBT) as a Reduced Intensity Conditioning Regimen Prior to Allogeneic Stem Cell Transplantatio[NCT00863148]	Phase 2	30 participants (Actual)	Interventional	2009-10-31	Completed
Safety and Efficacy Study of Busulfan/FLAG Conditioning Regimen in Patients With Relapsed/Refractory Acute Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation[NCT02784561]	Phase 4	80 participants (Anticipated)	Interventional	2016-07-31	Not yet recruiting
Sequential Intensive Chemotherapy Followed by Allogeneic Stem Cell Transplantation With Reduce-intensity Conditioning for Refractory and Relapse Acute Myeloid Leukemia in Adult Patients[NCT01496547]	Phase 2	47 participants (Actual)	Interventional	2011-01-31	Completed
Total Body Irradiation/ Fludarabine/ Busulfan/ Cyclophosphamide (TFBC) Combined With Umbilical Cord Blood Transplantation (UCBT) in the Treatment of High-risk Malignant Hematological Diseases[NCT05929092]		40 participants (Anticipated)	Interventional	2023-06-01	Recruiting
Randomized Study Comparing i.v. Busulfan (Busilvex®) Plus Fludarabine (BuFlu) Versus Busilvex® Plus Cyclophosphamide (BuCy2) as Conditioning Regimens Prior AlloHSCT in Patients (Age >= 40 and =<65 Years) With AML in Complete Remission.[NCT01191957]	Phase 3	252 participants (Actual)	Interventional	2008-01-31	Completed
A Phase II Study Of Allogeneic Transplant For Older Patients With AML In First Morphologic Complete Remission Using A Non-Myeloablative Preparative Regimen[NCT00070135]	Phase 2	121 participants (Actual)	Interventional	2004-01-31	Completed
Composite Health Assessment Risk Model (CHARM) for Older Adults: Applying Pre-Transplant Comorbidity, Geriatric Assessment, and BioMarkers on Non-Relapse Mortality After Allogeneic Transplant (BMT CTN 1704)[NCT03992352]		1,229 participants (Actual)	Observational	2019-07-19	Active, not recruiting
Prospective and Multicentre Evaluation of 3 Different Doses of IV Busulfan Associated With Fludarabine and Thymoglobuline in the Conditioning of Allogeneic Stem Cell Transplantation (SCT) From a Matched Related or Unrelated Donor in Patients With Poor Pro[NCT01985061]	Phase 2	177 participants (Anticipated)	Interventional	2013-12-31	Recruiting
Phase I Study of MDR Modulation With PSC-833 (NSC# 648265) With a Pilot Study of Cytogenetic Risk-Adapted Consolidation Followed by a Phase II Pilot Study of Immunotherapy With RIL-2 (NSC # 373364) in Previously Untreated Patients With AML< 60 Years[NCT00002925]	Phase 1/Phase 2	410 participants (Actual)	Interventional	1997-02-28	Completed
Busulfan-Fludarabine-Clofarabine With Allogeneic Stem Cell Transplantation for Advanced Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Advanced, Gleevec Refractory Chronic Myeloid Leukemia. A Randomized Phase II Study.[NCT00469014]	Phase 2	72 participants (Actual)	Interventional	2006-09-30	Completed
Unrelated Donor Hematopoietic Stem Cell Transplantation After Nonmyeloablative Conditioning For Patients With Hematological Malignancies[NCT00627666]	Phase 2	52 participants (Anticipated)	Interventional	2003-01-31	Completed
Feasibility Study of the Use of Intermediate Doses of Cytarabine Associated With Autologous Hematopoietic Stem Cells as Consolidation Treatment of Young Adults With Low- or Intermediate-risk de Novo Acute Myeloid Leukemia[NCT03023384]		547 participants (Anticipated)	Observational [Patient Registry]	2016-12-31	Recruiting
A Pilot Study of Gemtuzumab Ozogamicin in Combination With Busulfan and Cyclophosphamide (Immunochemotherapy) and Allogeneic Stem Cell Transplantation in Patients With High Risk Acute Myelogenous Leukemia and Myelodysplastic Syndrome[NCT02221310]	Phase 2	25 participants (Anticipated)	Interventional	2011-12-07	Completed
Clinical Phase II Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With Acute Myeloid Leukaemia[NCT01063660]	Phase 2	75 participants (Actual)	Interventional	2004-03-31	Completed
Effects of Adipose Derived Stem Cell Therapy in Women With Premature Ovarian Failure[NCT01853501]	Phase 4	4 participants (Anticipated)	Interventional	2012-09-30	Enrolling by invitation
Single Arm Phase II Study of Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia (ALL) in Older Patients Using Fludarabine and Total Body Irradiation (FluTBI) Regimen[NCT01991457]	Phase 2	19 participants (Actual)	Interventional	2013-08-27	Completed
The Study of New RIC Regimen of BuFlu in Older or Intolerable Patients With Hematologic Malignant Diseases[NCT01828619]		60 participants (Anticipated)	Observational	2013-02-28	Enrolling by invitation
PRO#1278: A Phase III Study of Fludarabine and Busulfan Versus Fludarabine, Busulfan and Low Dose Total Body Irradiation in Patients Receiving an Allogeneic Hematopoietic Stem Cell Transplant[NCT01366612]	Phase 3	53 participants (Actual)	Interventional	2010-06-16	Terminated (stopped due to Lack of Accrual)
A Phase II Study of Pevonedistat (MLN4924, TAK924) and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remission Acute Myelogenous Leukemia[NCT03709576]	Phase 2	3 participants (Actual)	Interventional	2018-07-18	Terminated (stopped due to Funding pulled)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Will be summarized with a proportion and a 95% confidence interval. (NCT01707004)
Timeframe: Up to 1 year

Cumulative Incidence of Grade III-IV Acute GVHD

Intervention	percentage (Number)
Decitabine + Bone Marrow Transplant	40.7

Determined by the standard bone marrow transplant (BMT) Clinical Trials Network criteria (BMTCTN). Will be analyzed using KM method, a Graft versus Host Disease (GVHD) grade III-IV will be obtained from the KM estimates along with 95% confidence intervals. (NCT01707004)
Timeframe: Day 100

Number of Participants With Complete Remission After Transplantation

Number of Participants With Primary Graft Failure

Intervention	percentage of participants (Number)
Decitabine + Bone Marrow Transplant	27.8

Intervention	Participants (Count of Participants)
Decitabine + Bone Marrow Transplant	14

Defined as less than 5% donor chimerism in the cluster of differentiation (CD)3 and CD33 selected cell populations at any time after transplantation. Will be analyzed using KM method. (NCT01707004)
Timeframe: Day 30

Overall Survival (OS)

Intervention	Participants (Count of Participants)
Decitabine + Bone Marrow Transplant	0

Will be analyzed using Kaplan-Meier (KM) method, and OS will be obtained from the KM estimates along with 95% confidence intervals. (NCT01707004)
Timeframe: Day 100

Percentage of Participants With Platelet Recovery by Day 30

Intervention	percentage of participants (Number)
Decitabine + Bone Marrow Transplant	64.7

Platelet recovery is defined as the first day of a platelet count greater than 20,000/mm^3 with no platelet transfusions. Will be summarized with mean and standard deviation or median and interquartile range, and the change will be tested using a one-sample paired t-test at a two-tailed significance level of 0.05. (NCT01707004)
Timeframe: Up to day 30

Progression Free Survival

Time to Neutrophil Recovery

Intervention	percentage with plt engraftment, day 30 (Number)
Decitabine + Bone Marrow Transplant	58

Intervention	days (Median)
Decitabine + Bone Marrow Transplant	141

Defined as achieving an absolute neutrophil count (ANC) greater than or equal to 500/ul for three consecutive measurements on different days. Will be summarized with mean and standard deviation or median and interquartile range, and the change will be tested using a one-sample paired t-test at a two-tailed significance level of 0.05. (NCT01707004)
Timeframe: Up to 1 year

Percentage of Participants With Chronic Graft-Versus-Host Disease (GVHD)

Intervention	days (Mean)
Decitabine + Bone Marrow Transplant	16

Chronic GVHD is classified per 2005 NIH Consensus Criteria (Filipovich et al. 2005) into categories of severity: none, mild, moderate, and severe. Occurrence of chronic GVHD is defined as the occurrence of mild, moderate, or severe chronic GVHD per this classification. (NCT01410344)
Timeframe: 1 Year Post-transplant

Percentage of Participants With Relapse/Progression

Intervention	percentage of participants (Number)
Allogeneic Transplant	17.6

Relapse/Progression is defined as relapse or progression of the primary malignancy. (NCT01410344)
Timeframe: 1 Year Post-transplant

Percentage of Participants Recovering Hematologic Function

Intervention	percentage of participants (Number)
Allogeneic Transplant	29.4

Recovery of hematologic function is described by the time to neutrophil and platelet recovery. Time to neutrophil recovery will be the first of three consecutive days of > 500 neutrophils/μL following the expected nadir. Time to platelet engraftment will be described by the date when platelet count is > 20,000/μL for the first of three consecutive labs with no platelet transfusions 7 days prior. (NCT01410344)
Timeframe: Days 28 and 100 Post-transplant

Percentage of Participants With Acute Graft-Versus-Host Disease (GVHD)

Intervention	percentage of participants (Number)
	Day 28 Neutrophil Recovery	Day 100 Platelet Recovery
Allogeneic Transplant	100.0	94.1

"Acute GVHD is graded according to the scoring system proposed by Przepiorka et al.1995:~Skin stage:~0: No rash~Rash <25% of body surface area~Rash on 25-50% of body surface area~Rash on > 50% of body surface area~Generalized erythroderma with bullous formation~Liver stage (based on bilirubin level)*:~0: <2 mg/dL 1.2-3 mg/dL 2.3.01-6 mg/dL 3.6.01-15.0 mg/dL 4.>15 mg/dL~GI stage*:~0: No diarrhea or diarrhea <500 mL/day~Diarrhea 500-999 mL/day or persistent nausea with histologic evidence of GVHD~Diarrhea 1000-1499 mL/day~Diarrhea >1500 mL/day~Severe abdominal pain with or without ileus * If multiple etiologies are listed for liver or GI, the organ system is downstaged by 1.~GVHD grade:~0: All organ stages 0 or GVHD not listed as an etiology I: Skin stage 1-2 and liver and GI stage 0 II: Skin stage 3 or liver or GI stage 1 III: Liver stage 2-3 or GI stage 2-4 IV: Skin or liver stage 4" (NCT01410344)
Timeframe: Day 100 Post-transplant

Percentage of Participants With Non-Relapse Mortality

Intervention	percentage of participants (Number)
	Grade II-IV Acute GVHD	Grade III-IV Acute GVHD
Allogeneic Transplant	41.2	11.8

The events for non-relapse mortality are death due to any cause other than relapse of the underlying malignancy. (NCT01410344)
Timeframe: Day 100, 1 Year, and 2 Years Post-transplant

Percentage of Participants With Overall Survival

Intervention	percentage of participants (Number)
	Day 100	1 Year	2 Years
Allogeneic Transplant	0.0	11.8	18.3

Overall survival is defined as the time from transplant to death from any cause. (NCT01410344)
Timeframe: Six months, 1 Year, and 2 Years Post-transplant

Chimerism

Intervention	percentage of participants (Number)
	6 Months	1 Year	2 Years
Allogeneic Transplant	82.4	58.8	50.2

Donor T-cell and myeloid chimerism will be described separately by conditioning regimen intensity (myeloablative or reduced intensity) according to proportions with mixed chimerism (5-95% donor cells out of all), full chimerism (>95% donor cells), or graft rejection (<5% donor cells). (NCT01410344)
Timeframe: Week 4, Day 100, and 6 months Post-transplant

Number of Participants With Primary Graft Failure

Intervention	Participants (Count of Participants)
	Week 472365409	Week 472365410	Day 10072365410	Day 10072365409	6 Months72365409	6 Months72365410
	Graft Rejection	No Assay Reported	Full Chimerism	Mixed Chimerism	Dead at Assessment
Reduced Intensity Allogeneic Transplant	4
Myeloablative Allogeneic Transplant	1
Myeloablative Allogeneic Transplant	3
Myeloablative Allogeneic Transplant	4
Reduced Intensity Allogeneic Transplant	5
Myeloablative Allogeneic Transplant	2
Reduced Intensity Allogeneic Transplant	2
Myeloablative Allogeneic Transplant	0
Reduced Intensity Allogeneic Transplant	0

Primary graft failure is defined by lack of neutrophil engraftment. (NCT01339910)
Timeframe: 28 days post-transplant

Number of Participants With Secondary Graft Failure

Intervention	Participants (Count of Participants)
Myeloablative Conditioning Regimen (MAC)	1
Reduced Intensity Conditioning (RIC)	3

Secondary graft failure is defined by initial neutrophil engraftment followed by subsequent decline in neutrophil counts to less than 500x10^6/liter that is unresponsive to growth factor therapy. (NCT01339910)
Timeframe: 18 months post-transplant

Percentage of Participants With Chronic GVHD

Intervention	Participants (Count of Participants)
Myeloablative Conditioning Regimen (MAC)	1
Reduced Intensity Conditioning (RIC)	4

Percentage of Participants With Disease Relapse

Intervention	percentage (Number)
Myeloablative Conditioning Regimen (MAC)	64.0
Reduced Intensity Conditioning (RIC)	47.6

Disease Relapse is defined as relapse of the primary disease. (NCT01339910)
Timeframe: 18 months post-randomization

Percentage of Participants With Overall Survival (OS)

Intervention	percentage (Number)
Myeloablative Conditioning Regimen (MAC)	13.5
Reduced Intensity Conditioning (RIC)	48.3

Overall survival is defined as survival of death from any cause. (NCT01339910)
Timeframe: 18 months post-randomization

Percentage of Participants With Relapse-Free Survival (RFS)

Intervention	percentage (Number)
Myeloablative Conditioning Regimen (MAC)	77.5
Reduced Intensity Conditioning (RIC)	67.7

Relapse-free survival is defined as survival without relapse of the primary disease. (NCT01339910)
Timeframe: 18 months post-randomization

Percentage of Participants With Treatment-related Mortality

Intervention	percentage (Number)
Myeloablative Conditioning Regimen (MAC)	67.8
Reduced Intensity Conditioning (RIC)	47.3

Treatment-related mortality is defined as death without a previous relapse of the primary disease. (NCT01339910)
Timeframe: 18 months post-randomization

Percentage of Participants With Acute Graft Versus Host Disease (GVHD)

Intervention	percentage (Number)
Myeloablative Conditioning Regimen (MAC)	15.8
Reduced Intensity Conditioning (RIC)	4.4

"Acute GVHD is graded according to the scoring system proposed by Przepiorka et al.1995:~Skin stage:~0: No rash~Rash <25% of body surface area~Rash on 25-50% of body surface area~Rash on > 50% of body surface area~Generalized erythroderma with bullous formation~Liver stage (based on bilirubin level)*:~0: <2 mg/dL~2-3 mg/dL~3.01-6 mg/dL~6.01-15.0 mg/dL~>15 mg/dL~GI stage*:~0: No diarrhea or diarrhea <500 mL/day~Diarrhea 500-999 mL/day or persistent nausea with histologic evidence of GVHD~Diarrhea 1000-1499 mL/day~Diarrhea >1500 mL/day~Severe abdominal pain with or without ileus * If multiple etiologies are listed for liver or GI, the organ system is downstaged by 1.~GVHD grade:~0: All organ stages 0 or GVHD not listed as an etiology I: Skin stage 1-2 and liver and GI stage 0 II: Skin stage 3 or liver or GI stage 1 III: Liver stage 2-3 or GI stage 2-4 IV: Skin or liver stage 4" (NCT01339910)
Timeframe: Day 100 post-transplant

Percentage of Participants With Neutrophil and Platelet Engraftment

Intervention	percentage (Number)
	Grade II-IV Acute GVHD	Grade III-IV Acute GVHD
Myeloablative Conditioning Regimen (MAC)	44.7	13.6
Reduced Intensity Conditioning (RIC)	31.6	6.8

Neutrophil engraftment is defined as achieving an absolute neutrophil count greater than 500x10^6/liter for 3 consecutive measurements on different days. The first of the 3 days will be designated the day of neutrophil engraftment. Platelet engraftment is defined as achieving platelet counts greater than 20,000/microliter for consecutive measurements over 7 days without requiring platelet transfusions. The first of the 7 days will be designated the day of platelet engraftment. Subjects must not have had platelet transfusions during the preceding 7 days. (NCT01339910)
Timeframe: Days 28 and 60 post-transplant

Number of Participants With Donor Cell Engraftment

Intervention	percentage (Number)
	Neutrophil Engraftment at Day 28	Platelet Engraftment at Day 60
Myeloablative Conditioning Regimen (MAC)	98.5	95.5
Reduced Intensity Conditioning (RIC)	97.8	96.2

Donor cell engraftment will be assessed by donor-recipient chimerism assays. Full donor chimerism is defined as the presence of at least 95% donor cells as a proportion of the total population in the peripheral blood or bone marrow. Graft rejection is defined as the presence of no more than 5% donor cells as a proportion of the total population. Mixed chimerism is defined as the presence of between 5% and 95% donor cells. Mixed or full donor chimerism will be considered evidence of donor engraftment. (NCT01339910)
Timeframe: Days 28 and 100 and 18 months post-transplant

2 Year DFS for All Patients

Intervention	Participants (Count of Participants)
	Day 2872548419	Day 2872548420	Day 10072548420	Day 10072548419	18 Months72548420	18 Months72548419
	Mixed Chimerism	Full Donor Chimerism	Graft Rejection	Death Prior to Assessment	Unknown (relapsed or missing assay)
Myeloablative Conditioning Regimen (MAC)	86
Reduced Intensity Conditioning (RIC)	80
Myeloablative Conditioning Regimen (MAC)	9
Reduced Intensity Conditioning (RIC)	30
Myeloablative Conditioning Regimen (MAC)	1
Myeloablative Conditioning Regimen (MAC)	0
Reduced Intensity Conditioning (RIC)	0
Myeloablative Conditioning Regimen (MAC)	36
Reduced Intensity Conditioning (RIC)	22
Myeloablative Conditioning Regimen (MAC)	106
Reduced Intensity Conditioning (RIC)	86
Myeloablative Conditioning Regimen (MAC)	12
Myeloablative Conditioning Regimen (MAC)	2
Myeloablative Conditioning Regimen (MAC)	6
Reduced Intensity Conditioning (RIC)	8
Myeloablative Conditioning Regimen (MAC)	71
Reduced Intensity Conditioning (RIC)	66
Myeloablative Conditioning Regimen (MAC)	4
Reduced Intensity Conditioning (RIC)	5
Reduced Intensity Conditioning (RIC)	1
Myeloablative Conditioning Regimen (MAC)	31
Reduced Intensity Conditioning (RIC)	42
Myeloablative Conditioning Regimen (MAC)	25
Reduced Intensity Conditioning (RIC)	19

Percentage of participants who were alive and relapse free at 2 years for all patients. The 2 year disease free survival, with 95% confidence interval, was estimated using the Kaplan Meier method. (NCT00070135)
Timeframe: Up to 2 years

2 Year Disease Free Survival In Unrelated Donor Recipient Group

Intervention	percentage of participants (Number)
Treatment (Fludarabine, Busulfan, Allogeneic PBSC)	42

"Percentage of participants who were alive and relapse free at 2 years for patients who were matched with an unrelated donor for transplant. The 2 year disease free survival, with 95% confidence interval, was estimated using the Kaplan Meier method.~A relapse is defined as any of the following:~Reappearance of leukemia blasts cells in peripheral blood~>5% blasts in the marrow, not attributable to another cause (e.g., bone marrow regeneration)~If there are no circulating blasts, but the marrow contains 5-20% blasts, a repeat bone marrow ≥ 1 week later with >5% blasts is necessary to meet the criteria for relapse~The development of extramedullary leukemia or leukemic cells in the cerebral spinal fluid" (NCT00070135)
Timeframe: 2 years

Non-relapse Mortality (NRM)

Intervention	percentage of participants (Number)
Treatment (Fludarabine, Busulfan, Allogeneic PBSC)	40

Percentage of patients who died due to causes other than relapse (NCT00070135)
Timeframe: Up to 5 years

Treatment Related Mortality

Intervention	percentage of patients (Number)
Treatment (Fludarabine, Busulfan, Allogeneic PBSC)	16

Number of participants with treatment related mortality (death) within the first 30 days following transplantation. (NCT00469014)
Timeframe: First 30 Days

Number of Subjects Disease-free Survival

Intervention	participants (Number)
Arm 1: Busulfan + Fludarabine (30 mg/m^2) + Clofarabine	0
Arm 2: Busulfan + Fludarabine (20 mg/m^2) + Clofarabine	0
Arm 3: Busulfan + Fludarabine (10 mg/m^2) + Clofarabine	0
Arm 4: Busulfan + Clofarabine	0

Percentage of patients without relapse of disease at 2 years (NCT01991457)
Timeframe: 2 years post-transplant

Intervention	Percent (Number)
Group 1	38.9
Group 2	18.8

Article	Year
Myeloablative conditioning regimens in adult patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation in complete remission: a systematic review and network meta-analysis. Bone marrow transplantation, 2023, Volume: 58, Issue:2 Topics: Adult; Bayes Theorem; Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Tra	2023
Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management. American journal of hematology, 2023, Volume: 98, Issue:9 Topics: Busulfan; Female; Humans; Janus Kinase 2; Leukemia, Myeloid, Acute; Leukocytosis; Male; Microcircula	2023
Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera? The oncologist, 2016, Volume: 21, Issue:4 Topics: Busulfan; Cell Proliferation; Humans; Hydroxyurea; Janus Kinase 2; Leukemia, Myeloid, Acute; Nitrile	2016
[Comparison of total body irradiation-cyclophosphamide versus busulphan-cyclophosphamide as conditioning regimens for myelogenous leukemia: a meta-analysis]. Zhongguo shi yan xue ye xue za zhi, 2008, Volume: 16, Issue:6 Topics: Busulfan; Cyclophosphamide; Disease-Free Survival; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acu	2008
Busulfan in hematopoietic stem cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2009, Volume: 15, Issue:5 Topics: Antineoplastic Agents; Busulfan; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid,	2009
High-dose etoposide in allogeneic stem cell transplantation. Cancer chemotherapy and pharmacology, 2012, Volume: 70, Issue:6 Topics: Adenine Nucleotides; Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chem	2012
RESPONSE OF ACUTE MYELOCYTIC LEUKEMIA TO CORTICOSTEROIDS. American journal of pharmacy and the sciences supporting public health, 1963, Volume: 135 Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Antineoplastic Agents; Busulfan; Cyclophosphamide; F	1963
Allogenic bone marrow transplantation: current status and future directions. Blood, 1983, Volume: 62, Issue:5 Topics: Anemia, Aplastic; Bone Marrow Transplantation; Busulfan; Cell Separation; Cyclophosphamide; Erythroc	1983
Allogeneic bone marrow transplantation for acute myelogenous leukemia, acute lymphocytic leukemia, and multiple myeloma following preparation with busulfan and cyclophosphamide (BuCy2). Seminars in oncology, 1993, Volume: 20, Issue:4 Suppl 4 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Moda	1993
Cytokine therapy for hematological malignancies. Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24 Suppl 1 Topics: Antineoplastic Agents; Busulfan; Clinical Trials as Topic; Cytokines; Follow-Up Studies; Granulocyte	1997
The treatment of chronic granulocytic leukaemia. Clinics in haematology, 1977, Volume: 6, Issue:1 Topics: BCG Vaccine; Busulfan; Cell Transformation, Neoplastic; Chromosomes, Human, 21-22 and Y; Humans; Leu	1977
Cell kinetics in chronic granuclotyci leukaemia (CGL). Clinics in haematology, 1977, Volume: 6, Issue:1 Topics: Busulfan; Cell Differentiation; Chromosomes, Human, 21-22 and Y; Feedback; Granulocytes; Hematopoies	1977
Patho-anatomical features of the bone marrow. Clinics in haematology, 1975, Volume: 4, Issue:2 Topics: Bone Marrow; Busulfan; Diagnosis, Differential; Erythropoiesis; Granulocytes; Humans; Leukemia, Myel	1975
[Allogeneic bone marrow transplantation in myeloid leukemia: chemical conditioning, clinical course and results]. Acta haematologica Polonica, 1992, Volume: 23, Issue:2 Suppl 1 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transpl	1992
Autologous bone marrow transplantation for acute myeloblastic leukemia in Europe: further evidence of the role of marrow purging by mafosfamide. European Co-operative Group for Bone Marrow Transplantation (EBMT). Leukemia, 1991, Volume: 5, Issue:10 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow Purging; Bone Marrow Transplantation; Bu	1991
High-dose chemotherapy with busulphan and cyclophosphamide and bone-marrow transplantation for drug-sensitive malignancies in adults: a preliminary report. The Medical journal of Australia, 1989, Oct-02, Volume: 151, Issue:7 Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamid	1989
Clinical studies of ABMT in acute myeloid leukaemia. Clinics in haematology, 1986, Volume: 15, Issue:1 Topics: Animals; Antineoplastic Agents; Bone Marrow; Bone Marrow Transplantation; Busulfan; Cyclophosphamide	1986
Current concepts in the treatment of chronic myelocytic leukemia. Annual review of medicine, 1973, Volume: 24 Topics: Antineoplastic Agents; Blood Platelet Disorders; Bromine; Busulfan; Dose-Response Relationship, Drug	1973
[Lactate dehydrogenase in human leukemia. A clinico-experimental study]. Verhandelingen - Koninklijke Vlaamse Academie voor Geneeskunde van Belgie, 1972, Volume: 34, Issue:5-6 Topics: Adult; Aged; Animals; Antibiotics, Antineoplastic; Bone Marrow; Bone Marrow Cells; Busulfan; Endotox	1972
[Current status of prognosis and the factors affecting it in adult leukemia and malignant lymphoma]. Naika. Internal medicine, 1967, Volume: 20, Issue:5 Topics: Adolescent; Adult; Busulfan; Hodgkin Disease; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloi	1967

Article	Year
Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active. Blood advances, 2021, 12-28, Volume: 5, Issue:24 Topics: Adult; Bridged Bicyclo Compounds, Heterocyclic; Busulfan; Hematopoietic Stem Cell Transplantation; H	2021
Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active. Blood advances, 2021, 12-28, Volume: 5, Issue:24 Topics: Adult; Bridged Bicyclo Compounds, Heterocyclic; Busulfan; Hematopoietic Stem Cell Transplantation; H	2021
Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active. Blood advances, 2021, 12-28, Volume: 5, Issue:24 Topics: Adult; Bridged Bicyclo Compounds, Heterocyclic; Busulfan; Hematopoietic Stem Cell Transplantation; H	2021
Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active. Blood advances, 2021, 12-28, Volume: 5, Issue:24 Topics: Adult; Bridged Bicyclo Compounds, Heterocyclic; Busulfan; Hematopoietic Stem Cell Transplantation; H	2021
A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation. Bone marrow transplantation, 2022, Volume: 57, Issue:8 Topics: Bayes Theorem; Busulfan; Clofarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation	2022
Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial. American journal of hematology, 2022, Volume: 97, Issue:8 Topics: Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, My	2022
Vorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-Term Study Outcomes. Transplantation and cellular therapy, 2022, Volume: 28, Issue:8 Topics: Acute Disease; Busulfan; Clofarabine; Drug Therapy, Combination; Graft vs Host Disease; Hematopoieti	2022
Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023, 01-10, Volume: 41, Issue:2 Topics: Adolescent; Adult; Aged; Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell	2023
Idarubicin plus BuCy versus BuCy conditioning regimens for intermediate-risk acute myeloid leukemia in first complete remission undergoing auto-HSCT: An open-label, multicenter, randomized phase 3 trial. American journal of hematology, 2023, Volume: 98, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Hematopoietic Stem Cell	2023
The effect of granulocyte-colony stimulating factor, decitabine, and busulfan-cyclophosphamide versus busulfan-cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from myelodyspl The Lancet. Haematology, 2023, Volume: 10, Issue:3 Topics: Anemia, Refractory, with Excess of Blasts; Busulfan; Chronic Disease; Cyclophosphamide; Decitabine;	2023
Conditioning therapy with N-acetyl-L-cysteine, decitabine and modified BUCY regimen for myeloid malignancies patients prior to allogeneic hematopoietic stem cell transplantation. American journal of hematology, 2023, Volume: 98, Issue:6 Topics: Acetylcysteine; Behavior Therapy; Busulfan; Decitabine; Graft vs Host Disease; Hematopoietic Stem Ce	2023
Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023, 10-10, Volume: 41, Issue:29 Topics: Adolescent; Adult; Aged; Busulfan; Cyclophosphamide; Drug Therapy, Combination; Graft vs Host Diseas	2023
Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome. Hematology/oncology and stem cell therapy, 2020, Volume: 13, Issue:3 Topics: Adult; Aged; Allografts; Busulfan; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Di	2020
Effect of the Thiotepa Dose in the TBF Conditioning Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission: A Report From the EBMT Acute Leukemia Working Party. Clinical lymphoma, myeloma & leukemia, 2020, Volume: 20, Issue:5 Topics: Adult; Aged; Allografts; Busulfan; Disease-Free Survival; Follow-Up Studies; Hematopoietic Stem Cell	2020
Decitabine induction with myeloablative conditioning and allogeneic hematopoietic stem cell transplantation in high-risk patients with myeloid malignancies is associated with a high rate of infectious complications. Leukemia research, 2020, Volume: 96 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; De	2020
Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 03-01, Volume: 39, Issue:7 Topics: Adult; Aged; Amsacrine; Busulfan; Cytarabine; Female; Graft vs Host Disease; Humans; Immunosuppressi	2021
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Apr-10, Volume: 35, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Cyclosporine;	2017
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Apr-10, Volume: 35, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Cyclosporine;	2017
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Apr-10, Volume: 35, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Cyclosporine;	2017
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Apr-10, Volume: 35, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Cyclosporine;	2017
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Apr-10, Volume: 35, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Cyclosporine;	2017
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Apr-10, Volume: 35, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Cyclosporine;	2017
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Apr-10, Volume: 35, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Cyclosporine;	2017
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Apr-10, Volume: 35, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Cyclosporine;	2017
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Apr-10, Volume: 35, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Cyclosporine;	2017
Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Jul-01, Volume: 35, Issue:19 Topics: Adult; Busulfan; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Graft vs Host Disease;	2017
Effects of two doses of anti-T lymphocyte globulin-Fresenius given after full-match sibling stem cell transplantation in acute myeloblastic leukemia patients who underwent myeloablative fludarabine/busulfan conditioning. Hematology/oncology and stem cell therapy, 2018, Volume: 11, Issue:3 Topics: Adult; Allografts; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Female; Graft vs Host Dise	2018
Preconditioning with fludarabine, busulfan and cytarabine versus standard BuCy2 for patients with acute myeloid leukemia: a prospective, randomized phase II study. Bone marrow transplantation, 2019, Volume: 54, Issue:6 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Cytar	2019
Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial. Haematologica, 2019, Volume: 104, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Fe	2019
Proteomic Profiling of Signaling Networks Modulated by G-CSF/Plerixafor/Busulfan-Fludarabine Conditioning in Acute Myeloid Leukemia Patients in Remission or with Active Disease prior to Allogeneic Stem Cell Transplantation. Acta haematologica, 2019, Volume: 142, Issue:3 Topics: Adult; Allografts; Benzylamines; Busulfan; Cyclams; Female; Granulocyte Colony-Stimulating Factor; H	2019
Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019, Volume: 25, Issue:9 Topics: Adult; Aged; Allografts; Busulfan; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female;	2019
Conditioning regimen with a 75% dose of standard busulfan/cyclophosphamide plus fludarabine before cord blood transplantation in older patients with AML and MDS. International journal of hematology, 2019, Volume: 110, Issue:3 Topics: Aged; Allografts; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Disease-Free Sur	2019
A prospective randomized toxicity study to compare reduced-intensity and myeloablative conditioning in patients with myeloid leukaemia undergoing allogeneic haematopoietic stem cell transplantation. Journal of internal medicine, 2013, Volume: 274, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Dose-Response Rel	2013
Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomes. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:7 Topics: Adult; Aged; Busulfan; Case-Control Studies; Cyclophosphamide; Drug Administration Schedule; Hematop	2013
A phase I study of CPX-351 in combination with busulfan and fludarabine conditioning and allogeneic stem cell transplantation in adult patients with refractory acute leukemia. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:7 Topics: Adult; Aged; Busulfan; Case-Control Studies; Cytarabine; Daunorubicin; Drug Administration Schedule;	2013
Hematopoietic stem cell transplantation in children and young adults with secondary myelodysplastic syndrome and acute myelogenous leukemia after aplastic anemia. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:3 Topics: Adolescent; Adult; Anemia, Aplastic; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool;	2014
Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:4 Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Female; Graft vs Host Disease; Hematopoietic S	2014
Extramedullary relapse following total marrow and lymphoid irradiation in patients undergoing allogeneic hematopoietic cell transplantation. International journal of radiation oncology, biology, physics, 2014, May-01, Volume: 89, Issue:1 Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Blast Crisis; Bone Marrow; Busulfan; Ch	2014
High-dose idarubicin plus busulfan as conditioning regimen to autologous stem cell transplantation: promising post-remission therapy for acute myeloid leukemia in first complete remission? Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:6 Topics: Adolescent; Adult; Busulfan; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation;	2014
Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial. Haematologica, 2014, Volume: 99, Issue:9 Topics: Adenine Nucleotides; Adult; Aged; Antilymphocyte Serum; Arabinonucleosides; Busulfan; Clofarabine; D	2014
Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. Annals of hematology, 2014, Volume: 93, Issue:12 Topics: Aged; Aged, 80 and over; Alkylating Agents; Blood Cell Count; Busulfan; Comorbidity; Disease Progres	2014
A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia. Clinical lymphoma, myeloma & leukemia, 2015, Volume: 15, Issue:6 Topics: Administration, Intravesical; Adult; Area Under Curve; Busulfan; Disease-Free Survival; Etoposide; H	2015
Busulfan and fludarabine conditioning regimen given at hematological nadir of cytoreduction fludarabine, cytarabine, and idarubicin chemotherapy in patients with refractory acute myeloid leukemia undergoing allogeneic stem cell transplantation: a single a Medicine, 2015, Volume: 94, Issue:15 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytarabine; Disease-Fre	2015
Busulfan and fludarabine conditioning regimen given at hematological nadir of cytoreduction fludarabine, cytarabine, and idarubicin chemotherapy in patients with refractory acute myeloid leukemia undergoing allogeneic stem cell transplantation: a single a Medicine, 2015, Volume: 94, Issue:15 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytarabine; Disease-Fre	2015
Busulfan and fludarabine conditioning regimen given at hematological nadir of cytoreduction fludarabine, cytarabine, and idarubicin chemotherapy in patients with refractory acute myeloid leukemia undergoing allogeneic stem cell transplantation: a single a Medicine, 2015, Volume: 94, Issue:15 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytarabine; Disease-Fre	2015
Busulfan and fludarabine conditioning regimen given at hematological nadir of cytoreduction fludarabine, cytarabine, and idarubicin chemotherapy in patients with refractory acute myeloid leukemia undergoing allogeneic stem cell transplantation: a single a Medicine, 2015, Volume: 94, Issue:15 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytarabine; Disease-Fre	2015
Reduced-Intensity Conditioning Combined with (188)Rhenium Radioimmunotherapy before Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: The Role of In Vivo T Cell Depletion. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:10 Topics: Aged; Alemtuzumab; Allografts; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens,	2015
Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Acute Lymphoid Leukemia. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:1 Topics: Adenine Nucleotides; Adult; Aged; Arabinonucleosides; Busulfan; Chronic Disease; Clofarabine; Female	2016
Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. The Lancet. Oncology, 2015, Volume: 16, Issue:15 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclop	2015
Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. The Lancet. Oncology, 2015, Volume: 16, Issue:15 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclop	2015
Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. The Lancet. Oncology, 2015, Volume: 16, Issue:15 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclop	2015
Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. The Lancet. Oncology, 2015, Volume: 16, Issue:15 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclop	2015
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncolo Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Dec-10, Volume: 33, Issue:35 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Drug Administ	2015
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncolo Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Dec-10, Volume: 33, Issue:35 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Drug Administ	2015
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncolo Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Dec-10, Volume: 33, Issue:35 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Drug Administ	2015
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncolo Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Dec-10, Volume: 33, Issue:35 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Drug Administ	2015
Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Children with Advanced Acute Leukemia with Fludarabine-, Busulfan-, and Melphalan-Based Conditioning. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:3 Topics: Acute Disease; Adolescent; Adult; Allografts; Busulfan; Child; Child, Preschool; Chronic Disease; Cy	2016
Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:4 Topics: Adult; Busulfan; Child; Child, Preschool; Cyclophosphamide; Female; Gene Expression; Graft vs Host D	2016
A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:4 Topics: Adolescent; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antilymphocyte Serum; Busulfan; Chil	2016
Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS. Bone marrow transplantation, 2016, Volume: 51, Issue:7 Topics: Adult; Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hepatic Veno-	2016
A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation. Bone marrow transplantation, 2017, Volume: 52, Issue:1 Topics: Adenine Nucleotides; Adult; Aged; Allografts; Arabinonucleosides; Busulfan; Clofarabine; Disease-Fre	2017
Continuous infusion idarubicin and intravenous busulphan as conditioning regimen to autologous stem cell transplantation for patients with acute myeloid leukaemia. Hematological oncology, 2009, Volume: 27, Issue:4 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality	2009
Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:3 Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined	2011
Favorable outcomes of intravenous busulfan, fludarabine, and 400 cGy total body irradiation-based reduced-intensity conditioning allogeneic stem cell transplantation for acute myelogenous leukemia with old age and/or co-morbidities. International journal of hematology, 2010, Volume: 92, Issue:2 Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busu	2010
Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:6 Topics: Adenine Nucleotides; Animals; Antilymphocyte Serum; Antineoplastic Agents; Arabinonucleosides; Busul	2011
Phase I trial and pharmacokinetic study of high-dose clofarabine and busulfan and allogeneic stem cell transplantation in adults with high-risk and refractory acute leukemia. Leukemia, 2011, Volume: 25, Issue:4 Topics: Adenine Nucleotides; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucle	2011
Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:10 Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival	2011
Clinical effect of reduced-intensity conditioning regimen containing antithymocyte globulin for hematopoietic cell transplantation from unrelated-donors. American journal of hematology, 2011, Volume: 86, Issue:5 Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Agents; Bone Marrow Transplantation; Busulfa	2011
Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. Blood, 2011, Dec-01, Volume: 118, Issue:23 Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents,	2011
Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:3 Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide;	2012
A Phase I study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophosphamide (Bu/Cy) and allogeneic stem cell transplantation in children with poor-risk CD33+ AML: a new targeted immunochemotherapy myeloablative conditioning (MAC) regim Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:2 Topics: Adolescent; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiat	2012
Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:6 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bone Marrow Transplant	2012
Allogeneic hematopoietic SCT in patients with AML following treosulfan/fludarabine conditioning. Bone marrow transplantation, 2012, Volume: 47, Issue:9 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Hematopoietic Stem Cell Tra	2012
Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity. Bone marrow transplantation, 2012, Volume: 47, Issue:10 Topics: Adult; Aged; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Myeloid,	2012
Dose escalation of total marrow irradiation with concurrent chemotherapy in patients with advanced acute leukemia undergoing allogeneic hematopoietic cell transplantation. International journal of radiation oncology, biology, physics, 2013, Jan-01, Volume: 85, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Busulfan; Combined Modality Ther	2013
Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicen Journal of hematology & oncology, 2013, Feb-08, Volume: 6 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Combined Modalit	2013
Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood, 2002, Sep-15, Volume: 100, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Follow-Up Studies; Gr	2002
Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Annals of hematology, 2003, Volume: 82, Issue:6 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality	2003
Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survival. Blood, 2004, May-15, Volume: 103, Issue:10 Topics: Adolescent; Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; C	2004
Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies. Bone marrow transplantation, 2004, Volume: 33, Issue:9 Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfa	2004
Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood, 2004, Sep-15, Volume: 104, Issue:6 Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neo	2004
Treosulfan/fludarabine: a new conditioning regimen in allogeneic transplantation. Annals of hematology, 2004, Volume: 83 Suppl 1 Topics: Busulfan; Humans; Leukemia; Leukemia, Myeloid, Acute; Leukocyte Transfusion; Lymphoma; Myelodysplast	2004
CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens. Bone marrow transplantation, 2005, Volume: 35, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Carmus	2005
Targeted busulfan and cyclophosphamide as compared to busulfan and TBI as preparative regimens for transplantation in patients with advanced MDS or transformation to AML. Leukemia & lymphoma, 2004, Volume: 45, Issue:12 Topics: Adolescent; Adult; Aged; Busulfan; Child; Child, Preschool; Cyclophosphamide; Female; Graft Rejectio	2004
Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Oct-01, Volume: 11, Issue:19 Pt 2 Topics: Adolescent; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD	2005
131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood, 2006, Mar-01, Volume: 107, Issue:5 Topics: Adolescent; Adult; Age Factors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco	2006
Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2007, Volume: 13, Issue:2 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool	2007
Non-myeloablative hematopoietic stem cell transplantation is of limited value in advanced or refractory acute myeloblastic leukemia. The Mexican experience. Hematology (Amsterdam, Netherlands), 2007, Volume: 12, Issue:3 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool	2007
Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2008, Volume: 14, Issue:6 Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Agents; Bayes Theorem; Busulfan; Combined Mo	2008
Immunotherapy for chronic myelogenous leukemia: survival not affected by treatment in the stable phase. Cancer research, 1984, Volume: 44, Issue:1 Topics: Adult; Busulfan; Clinical Trials as Topic; Combined Modality Therapy; Follow-Up Studies; Humans; Hyd	1984
Chemotherapy of the myeloid leukaemias. Journal of the Royal College of Physicians of London, 1980, Volume: 14, Issue:1 Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Busulfan; Child; Clinical Trials as	1980
Combined transplantation of allogeneic bone marrow and CD34+ blood cells. Blood, 1995, Oct-01, Volume: 86, Issue:7 Topics: Adult; Antigens, CD; Antigens, CD34; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cyclos	1995
Busulfan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia. Blood, 1994, Oct-01, Volume: 84, Issue:7 Topics: Administration, Oral; Adolescent; Age Factors; Bone Marrow Transplantation; Busulfan; Child; Child,	1994
Allogeneic bone marrow transplantation in children with acute myelogenous leukemia in first remission. Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP) and the Gruppo Italiano per il Trapianto di Midollo Osseo (GITMO). Bone marrow transplantation, 1994, Volume: 13, Issue:6 Topics: Adolescent; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therap	1994
Childhood acute myeloid leukemia: outcome in a single center using chemotherapy and consolidation with busulfan/cyclophosphamide for bone marrow transplantation. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:10 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; C	1994
Allogeneic bone marrow transplantation following busulfan and 90 mg/kg of cyclophosphamide. Bone marrow transplantation, 1993, Volume: 12, Issue:6 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combin	1993
Allogeneic bone marrow transplantation for acute myelogenous leukemia, acute lymphocytic leukemia, and multiple myeloma following preparation with busulfan and cyclophosphamide (BuCy2). Seminars in oncology, 1993, Volume: 20, Issue:4 Suppl 4 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Moda	1993
Busulfan/etoposide--initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with acute nonlymphoblastic leukemia. Blood, 1993, Jan-15, Volume: 81, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantat	1993
Autologous bone marrow transplantation in late first complete remission improves outcome in acute myelogenous leukemia. Leukemia, 1996, Volume: 10, Issue:3 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu	1996
Busulfan, cyclophosphamide and fractionated total body irradiation for allogeneic marrow transplantation in advanced acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels. Bone marrow transplantation, 1996, Volume: 17, Issue:3 Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols	1996
Late effects of allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: the impact of conditioning regimen without total-body irradiation--a report from the Société Française de Greffe de Moelle. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:6 Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone	1997
Autologous peripheral blood progenitor cell transplantation mobilized with high-dose cytarabine in acute myeloid leukemia in first complete remission. Annals of oncology : official journal of the European Society for Medical Oncology, 1998, Volume: 9, Issue:2 Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purgi	1998
The role of thiotepa in autologous bone marrow transplantation for acute leukemia. Leukemia research, 1998, Volume: 22, Issue:11 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu	1998
Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide. Bone marrow transplantation, 1999, Volume: 24, Issue:9 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combi	1999
Hematopoietic stem cell transplantation (HSCT) with a conditioning regimen of busulfan, cyclophosphamide, and etoposide for children with acute myelogenous leukemia (AML): a phase I study of the Pediatric Blood and Marrow Transplant Consortium. Medical and pediatric oncology, 2000, Volume: 35, Issue:4 Topics: Adolescent; Alberta; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Prescho	2000
Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. American journal of hematology, 2001, Volume: 67, Issue:4 Topics: Adolescent; Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents, Alkylating; Bon	2001
Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood, 2001, Dec-15, Volume: 98, Issue:13 Topics: Adolescent; Adult; Alopecia; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cycloph	2001
Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:4 Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Cladribine; Combined Modality Therapy; Graf	2002
Autologous and allogeneic bone marrow transplantation for childhood acute nonlymphoblastic leukemia. Transplantation proceedings, 1992, Volume: 24, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Cyclophosphamide; Cyclosporine; Fol	1992
Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide. Blood, 1992, May-15, Volume: 79, Issue:10 Topics: Actuarial Analysis; Adult; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Female; Follow-U	1992
[Autotransplantation in acute nonlymphoid leukemia]. Haematologica, 1991, Volume: 76 Suppl 3 Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transpla	1991
Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2. Blood, 1991, Aug-01, Volume: 78, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combin	1991
Busulfan, cyclophosphamide, and melphalan conditioning for autologous bone marrow transplantation in hematologic malignancy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991, Volume: 9, Issue:10 Topics: Actuarial Analysis; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantati	1991
Drug-mediated marrow purging: mafosfamide in adult acute leukemia in remission. The experience of the Italian study group. Bone marrow transplantation, 1989, Volume: 4 Suppl 1 Topics: Adolescent; Adult; Bone Marrow; Bone Marrow Transplantation; Busulfan; Child; Cyclophosphamide; Drug	1989

busulfan and Acute Myelogenous Leukemia

Research Excerpts

Research

Studies (411)

Authors

Clinical Trials (28)

Trial Overview

Trial Outcomes

Cumulative Incidence of Chronic GVHD According to BMTCTN

Cumulative Incidence of Grade III-IV Acute GVHD

Number of Participants With Complete Remission After Transplantation

Number of Participants With Primary Graft Failure

Overall Survival (OS)

Percentage of Participants With Platelet Recovery by Day 30

Progression Free Survival

Time to Neutrophil Recovery

Percentage of Participants With Chronic Graft-Versus-Host Disease (GVHD)

Percentage of Participants With Relapse/Progression

Percentage of Participants Recovering Hematologic Function

Percentage of Participants With Acute Graft-Versus-Host Disease (GVHD)

Percentage of Participants With Non-Relapse Mortality

Percentage of Participants With Overall Survival

Chimerism

Number of Participants With Primary Graft Failure

Number of Participants With Secondary Graft Failure

Percentage of Participants With Chronic GVHD

Percentage of Participants With Disease Relapse

Percentage of Participants With Overall Survival (OS)

Percentage of Participants With Relapse-Free Survival (RFS)

Percentage of Participants With Treatment-related Mortality

Percentage of Participants With Acute Graft Versus Host Disease (GVHD)

Percentage of Participants With Neutrophil and Platelet Engraftment

Number of Participants With Donor Cell Engraftment

2 Year DFS for All Patients

2 Year Disease Free Survival In Unrelated Donor Recipient Group

Non-relapse Mortality (NRM)

Treatment Related Mortality

Number of Subjects Disease-free Survival

To Compare the Relapse Rate at 1 Year of Patients With Myeloid Malignancies Receiving Each Treatment

Reviews

Trials

Other Studies